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Executive Summary 
Introduction 
Health Problem 
In the scope of this assessment, primary and secondary lymphoedema is the 
condition of interest. Lymphoedema is a chronic disease and requires treat-
ment. It can occur at any age – in childhood, primary forms are more common 
[1]. Overall, lymphoedema can be congenital or acquired, so-called primary 
(congenital abnormality or malfunction in the lymphatic system) and second-
ary lymphoedema (caused by defects to the lymphatic system, usually due to 
cancer treatment, infection, or trauma) [2-4]. 
There is no cure for lymphoedema [2, 5, 6]. Without appropriate manage-
ment, lymphoedema may worsen causing pain and comprise body image dis-
turbances, infections, restrictions in range of motion (functional impairment/ 
restricted mobility), swelling, cellulitis, and a decrease in patients’ QoL with 
functional, aesthetic, and psychic repercussions (e.g., feeling of tightness, 
heavy feeling, narrowness of clothing, shoes and jewellery, and skin altera-
tions). It may also lead to irreversible changes like fibrosis or the excess of 
adipose tissue. These patient-reported symptoms can occur individually or 
in combination [1, 7-11]. 
Description of Technology 
The aim of LVA is to restore lymphatic circulation and bypass obstructions 
in lymphatics by constructing an alternative lymph drainage pathway [12]. 
The procedure anastomoses distal subdermal lymphatic vessels and adjacent 
venules with the diameter of less than 0.8 mm [13, 14]. Therefore, a connec-
tion of functioning lymphatic vessels and similarly sized subdermal venules 
is made to allow unidirectional flow of lymphatic fluid directly into the ve-
nous system, meaning that the lymph does not need to pass the damaged lym-
phatic area to return to the circulation [5, 15, 16]. 
LVA can be performed in four basic ways: end-to-end, side-to-side, end-to-
side, and side-to-end [17, 18]. The procedure is technically demanding, time-
consuming, and requires a specialized team with experience in microsurgi-
cal techniques [19]. The procedure is performed under microscope with max-
imum magnification and therefore, specifically designed supermicrosurgical 
instruments as well as suture material with the size of 11.0 and 12.0 are re-
quired. Further, to map healthy and functioning lymphatic vessels and to 
approve the patency of the anastomosis, one recent technological advance in 
LVA procedures is the use of indocyanine green (ICG) fluorescence lymphan-
giography [20]. Ongoing anastomosis patency can be confirmed during follow-
up with lymphoscintigraphy or ICG lymphography [16, 20, 21]. 
Research question 
Is lymphovenous anastomosis in comparison to conservative or other surgical 
treatments (e.g., lymph node transfer/transplantation) in patients with lym-
phoedema stage I, II and III more effective and safer concerning pain, func-
tionality, quality of life (QoL), recurrence or complications? 
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Methods 
To answer the research questions on efficacy and safety-related outcomes, a 
systematic literature search in four databases was conducted. In addition, we 
performed a manual search and screened information provided by the sub-
mitting hospital to identify further relevant studies. The study selection, data 
extraction, and assessing the methodological quality of the studies was per-
formed by two independent researchers. 
Domain effectiveness 
The following efficacy-related outcomes were used as evidence to derive a 
recommendation: QoL, pain, functionality, and recurrence. 
Domain safety 
The following safety-related outcomes were used as evidence to derive a rec-
ommendation: adverse events (procedure-related and not procedure-related). 
 
Results 
Available evidence 
A total of one non-randomized controlled study and four prospective single-
arm studies were eligible for inclusion in the current report. A cut-off of more 
than or even 10 patients was defined as an inclusion criterion for prospective 
single-arm studies. 
Overall, data on efficacy and safety was evaluated in 56 and 217 patients, 
respectively. 
Clinical effectiveness 
To assess the effectiveness of LVA for lymphoedema, we could only identify 
one non-randomized controlled study (NRCT) with a total of 43 patients as-
sessing the effectiveness of LVA compared to 13 patients with vascularized 
supraclavicular lymph node transfer (VSLNT). 
No evidence was found on the crucial outcomes pain, functionality, and re-
currence. 
Only the NRCT assessed the important outcome on changes in the postopera-
tive volume. The comparison was made between the LVA and the VSLNT 
group using the Lower Extremity Lymphoedema index (LEL). The mean 
changes of volume compared with preoperative volumes were statistical sig-
nificant in the VSLNT group [22]. 
Safety 
One NRCT could be identified for the safety assessment of LVA (43 patients) 
and VSLNT (13 patients). Further, safety outcomes were evaluated in four 
prospective single-arm studies (161 patients). 
In the LVA group of the NRCT, no adverse events were reported compared 
to the VSLNT group, where adverse events were reported in three patients 
who completed the follow-up, out of 13 patients (23.1%), with statistical sig-
nificance in favor of LVA. 
systematic  
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Overall, procedure-related adverse events occurred in two patients who com-
pleted the follow-up, out of 161 included patients across the prospective sin-
gle-arm studies (1.2%). 
None of the studies reported on procedure unrelated adverse events. 
Upcoming evidence 
Currently, there are three ongoing randomized controlled trials, which might 
show effects of LVA with a higher quality of evidence: two ongoing RCTs eval-
uate LVA compared to complex decongestive therapy (NCT02790021 & JPRN-
UMIN000025137), and one ongoing pilot study evaluating the efficacy of ro-
bot-assisted LVA in comparison to conventional LVA (NTR6465). 
Furthermore, 8 ongoing parallel non-randomized (n=4) and single-arm non-
randomized studies (n=4) could be identified. 
Reimbursement 
At this point in time, the use of LVA for the treatment of lymphoedema is 
not reimbursed by the Austrian health care system. 
 
Discussion 
Overall, the strength of evidence for the effectiveness and safety of LVA was 
very low due to high risk of bias in the NRCT, the observational study design, 
insufficient outcome reporting, and small sample sizes. 
The overall risk of bias was considered moderate to high because no randomi-
zation or blinding was performed, and because of insufficient reporting on 
critical outcomes (e.g. QoL), unclear reporting of confounding variables, and 
patients’ consecutive recruitment. 
The included studies in this report demonstrate mixed results following the 
LVA procedures and the quality of these studies varies. A major concern of 
most of the identified prospective interventional single-arm studies is the low 
number of included patients. In order to identify rare procedure related ad-
verse events, low patient numbers are insufficient. Another essential issue are 
the follow-up periods in the included studies. Yet, only one study had a long-
er follow-up period of 12 months [20]. Therefore, reliable data of long-term 
safety and efficacy outcomes are missing. Another limitation of this review is 
that the studies included varied in terms of stages of lymphoedema, localisa-
tion of lymphoedema (upper or lower extremity), and outcomes were not re-
ported separately on primary and secondary lymphoedema, which may lead 
to a variation in efficacy and safety of the results. 
Nevertheless, LVA seems to be safe for the treatment of primary and sec-
ondary lymphoedema. However, no controlled evidence for crucial outcomes 
could be identified evaluating LVA and a comparator. Patient-relevant out-
comes such as QoL were only described in uncontrolled studies and incon-
sistently reported. Because the included studies showed poor quality of evi-
dence and high risk of bias, it is not possible to draw a reliable conclusion on 
the clinical effectiveness of LVA. 
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Further, there were various methods of LVA performed in the studies, data 
on upper extremity lymphoedema was reported more frequently, and the es-
timation of ongoing post-interventional treatments (e.g., compression treat-
ment etc.) is scarce and presented a large variety. Future RCTs and/or pro-
spective NRCTs need to be performed to find the optimal lymphoedema man-
agement algorithm and to help determine the exact patient group that would 
benefit most from the procedure. In addition, these studies need to be con-
ducted to confirm the outcomes, especially on QoL, and to further knowledge 
of this field. 
 
Conclusion 
On the basis of the available evidence, we cannot conclude if the assessed pro-
cedure LVA is at least equally effective and safer as the comparator VLNT or 
conservative treatment. Due to the methodological shortcomings of the avail-
able evidence, no conclusions are made about the effectiveness of the proce-
dure. There is a need for high-quality studies due to consistent positive find-
ings based on observational evidence with respect to limb volume reduction. 
Concerning safety outcomes, only procedure-related complications were re-
ported based upon data from one NRCT and four prospective interventional 
single-arm studies. These suggest a relatively safe profile of LVA. New study 
results based on a high-quality RCT will potentially influence the effect es-
timate considerably. 
The re-evaluation is recommended after 2021, if the potentially relevant on-
going studies are completed and only if patient-relevant outcomes are includ-
ed to derive a recommendation. Otherwise, still no conclusions can be drawn 
on patient-relevant outcomes. 
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Zusammenfassung 
Einleitung 
Indikation und therapeutisches Ziel 
Der Fokus dieser systematischen Übersichtsarbeit liegt auf primären und 
sekundären Lymphödemen. 
Ein Lymphödem ist eine chronische, entzündliche Erkrankung, die eine Be-
handlung erfordert. Die Erkrankung kann angeboren oder erworben sein, so 
genannte primäre (kongenitale Fehlbildung oder Fehlfunktion des lympha-
tischen Systems) und sekundäre Lymphödeme (verursacht durch Defekte des 
lymphatischen Systems, in der Regel aufgrund von Krebsbehandlungen, In-
fektion oder Trauma) [2-4]. Lymphödeme können in jedem Alter auftreten – 
primäre Formen sind in der Kindheit häufiger [1]. 
Der Krankheitsverlauf ist variabel [23]. Ein Lymphödem entsteht aus einer 
Zusammensetzung proteinreicher Flüssigkeit im interstitiellen Raum mit an-
fänglichen Symptomen eines weichen, pittierenden Ödems in der betroffenen 
Extremität. Dies kann eine Entzündung des Gewebes und eine Stimulation 
der Fibrose verursachen. Die Verschlechterung der lymphatischen Funktion 
führt ferner zu Ablagerungen im Unterhautgewebe. Diese Faktoren beeinflus-
sen das Lymphödem, wodurch es zu einer Verschlechterung der Symptome 
kommt und zu einer dicken, fibrotischen, fettigen, ödematösen und schmerz-
haften Extremität fortschreitet, die die täglichen Aktivitäten der PatientIn-
nen beeinträchtigen [23]. 
Lymphödeme können nicht vollständig geheilt werden [2, 5, 6]. Ohne entspre-
chende Behandlung kann sich das Lymphödem verschlechtern und Schmer-
zen verursachen. Dazu gehören Körperbildstörungen, Infektionen, Einschrän-
kungen des Bewegungsumfangs (funktionelle Beeinträchtigung/eingeschränk-
te Mobilität), Schwellungen, Zellulitis und eine Abnahme der Lebensquali-
tät der PatientInnen mit funktionellen, ästhetischen, und psychischen Aus-
wirkungen (z. B. Engegefühl, Schweregefühl, Enge von Kleidung, Schuhen 
und Schmuck sowie Hautveränderungen) [1, 7-11]. 
Beschreibung der Technologie 
Das Ziel einer lymphovenösen Anastomose (LVA) ist die Wiederherstellung 
des lymphatischen Kreislaufs und die Umgehung von Hindernissen in Lymph-
gefäßen durch den Aufbau eines alternativen Lymphdrainageweges [12]. Das 
Verfahren anastomosiert distale, subdermale Lymphgefäße und angrenzende 
Venolen mit einem Durchmesser von weniger als 0,8 mm [13, 14]. Somit wird 
eine Verbindung von funktionierenden Lymphgefäßen und ähnlich großen 
subdermalen Venolen hergestellt, um eine unidirektionale Strömung der 
Lymphflüssigkeit in das Venensystem zu ermöglichen. Die Lymphe muss 
demnach den beschädigten Lymphbereich nicht passieren, um in den Blut-
kreislauf zurückzukehren [5, 15, 16]. Um eine dauerhafte Verbesserung des 
Lymphödems zu erreichen, sind subdermale Venolen vorteilhafter, da der 
Blutdruck niedriger ist als in den tiefen, größeren Venen, wodurch es zu ei-
nem geringeren venösen Rückfluss kommt [24, 25]. 
Fokus: primäre und 
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entzündliche und 
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Erkrankung verursacht 
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LVA kann auf vier grundlegende Arten durchgeführt werden: End-zu-End, 
Seit-zu-Seit, End-zu-Seit und Seit-zu-End [17, 18]. Das Verfahren ist tech-
nisch anspruchsvoll, zeitaufwendig und erfordert ein spezialisiertes Team mit 
Erfahrung in mikrochirurgischen Techniken [19]. Die Verwendung geeigne-
ter Bildgebungswerkzeuge zur Dokumentation der Wirksamkeit ist zudem 
erforderlich. Wird eine LVA im frühen Krankheitsverlauf der Lymphödeme 
durchgeführt – bevor Schäden an der lymphatischen Wand und eine beein-
trächtigte lymphatische Kontraktilität aufgetreten sind – wird ein größerer 
und länger anhaltender Nutzen vermutet [15]. 
Das Verfahren wird unter einem Mikroskop mit maximaler Vergrößerung 
durchgeführt. Aus diesem Grund sind speziell konstruierte supermikrochi-
rurgische Instrumente sowie Nahtmaterial mit der Größe von 11,0 und 12,0 
erforderlich. Um gesunde und funktionierende Lymphgefäße darzustellen 
und die Durchgängigkeit der Anastomose zu bestätigen, kann zusätzlich zur 
LVA die Verwendung der Indocyaningrün (ICG) Fluoreszenz Lymphangio-
graphie als neuer technologischer Fortschritt im Zusammenhang mit dem 
Verfahren der LVA angewendet werden [20]. Die Durchgängigkeit der Anas-
tomosen kann zusätzlich während einer Nachuntersuchung mit Lymphszin-
tigraphie oder ICG-Lymphographie bestätigt werden [16, 20, 21]. 
Wissenschaftliche Fragestellung 
Sind lymphovenöse Anastomosen im Vergleich zu konservativen oder ande-
ren chirurgischen Behandlungen (z. B. Lymphknotentransfer/-transplanta-
tion) bei PatientInnen mit Lymphödemen Stadium I, II und III im Hinblick 
auf Schmerzen, Funktionalität, Lebensqualität, Rezidiven und Komplikati-
onen wirksamer und sicherer? 
 
Methoden 
Die Beantwortung der Forschungsfrage bezüglich Wirksamkeit und Sicher-
heit erfolgte anhand einer systematischen Literatursuche in folgenden Da-
tenbanken: 
 Medline via Ovid 
 Embase 
 The Cochrane Library 
 CRD (DARE, NHS-EED, HTA). 
Zusätzlich wurde eine Handsuche durchgeführt. Die Studienauswahl, Daten-
extraktion sowie die Bewertung der methodischen Qualität der Studien er-
folgte unabhängig durch zwei AutorInnen. Insgesamt wurden 629 Zitate iden-
tifiziert wovon fünf Publikationen (eine nicht-randomisierte kontrollierte Stu-
die und vier prospektive einarmige Studien) für eine Datensynthese einge-
schlossen wurden. 
Darüber hinaus wurden in der systematischen Literatursuche 14 systemati-
sche Übersichtsarbeiten und Health Technology Assessments zu LVA bei 
Lymphödemen gefunden, die aufgrund methodischer Unterschiede (z. B. an-
dere Studienziele, Einschluss retrospektiver Studien) von der Analyse aus-
geschlossen wurden. 
Zusätzlich wurde eine Suche in drei klinischen Studienregistern (Clinical-
Trials.gov, WHO-ICTRP, EU Clinical Trials) durchgeführt, um laufende und 
unveröffentlichte Studien zu identifizieren. Die Suche resultierte in 15 Tref-
fern, wovon elf Studien als potentiell relevant eingeschätzt wurden. 
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Die Daten, der für die Entscheidung herangezogenen Endpunkte, wurden aus 
den einzelnen Studien extrahiert und zusammengefasst und nach GRADE 
(Grading of Recommendations Assessment, Development and Evaluation) be-
wertet. 
Klinische Wirksamkeit 
Zur Bewertung der Wirksamkeit wurden die folgenden entscheidenden 
Endpunkte für eine Empfehlung herangezogen: 
 Lebensqualität (QoL) 
 Schmerzen 
 Funktionalität 
 Rezidive. 
Sicherheit 
Zur Bewertung der Sicherheit wurden die folgenden entscheidenden  
Endpunkte für eine Empfehlung herangezogen: 
 Komplikationen 
 unerwünschte Ereignisse (verfahrensbezogen) 
 unerwünschte Ereignisse (nicht-verfahrensbezogen). 
 
Ergebnisse 
Verfügbare Evidenz 
Insgesamt konnte eine nicht-randomisierte kontrollierte Studie (NRCT) und 
vier prospektive einarmige Studien identifiziert werden, die den Einschluss-
kriterien des vorliegenden Berichts entsprachen. Für prospektive einarmige 
Studien wurde ein Cut-Off von zehn oder mehr PatientInnen als Einschluss-
kriterium festgelegt. 
Ausgewertet wurden Daten zur Wirksamkeit und Sicherheit von insgesamt 
56 bzw. 217 PatientInnen. 
Klinische Wirksamkeit 
Zur Beurteilung der Wirksamkeit der LVA für die Behandlung von Lymph-
ödemen konnte nur eine nicht-randomisierte kontrollierte Studie (NRCT) mit 
insgesamt 43 PatientInnen im Vergleich zu 13 PatientInnen mit vaskularisier-
tem supraklavikulärem Lymphknotentransfer (VSLNT) identifiziert werden. 
Zu den kritischen Endpunkten Schmerz, Funktionalität und Rezidiven wurde 
keine Evidenz gefunden. 
Die einzige NRCT bewertete den wichtigen Endpunkt der Veränderungen des 
postoperativen Volumens. Der Vergleich wurde zwischen der LVA- und der 
VSLNT-Gruppe unter Verwendung des Lower-Extremity-Lymphödem-Index 
(LEL) durchgeführt. Die mittleren Volumenveränderungen gegenüber den 
präoperativen Volumina waren in der VSLNT-Gruppe statistisch signifikant 
[22]. 
 
Studienbewertung  
nach GRADE 
entscheidende 
Endpunkte für 
Wirksamkeit ... 
... und Sicherheit 
1 nicht-randomisierte 
kontrollierte Studie und 
4 prospektive einarmige 
Studien 
nur 1 nicht-
randomisierte 
kontrollierte Studie 
keine Evidenz zu 
kritischen Endpunkten 
wichtiger Endpunkt 
„Veränderungen des 
postoperativen 
Volumens“ in  
VSLNT-Gruppe 
statistisch signifikant 
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Sicherheit 
Für die Beurteilung der Sicherheit von LVA (43 PatientInnen) und VSLNT 
(13 PatientInnen) konnte die identifizierte NRCT ebenfalls herangezogen 
werden. Darüber hinaus wurden die Sicherheitsendpunkte in vier prospek-
tiven einarmigen Studien (161 PatientInnen) berichtet. 
In der NRCT Studie wurden in der LVA-Gruppe keine unerwünschten Er-
eignisse und in der VSLNT-Gruppe bei drei von insgesamt 13 PatientInnen 
(23,1 %), die das Follow-Up durchliefen, unerwünschte Ereignisse mit statis-
tischer Signifikanz zugunsten der LVA berichtet. 
Für die Sicherheitsanalyse können auch verfahrensbezogene Komplikationen 
von prospektiven einarmigen Studien in Betracht gezogen werden, da diese 
direkt dem Eingriff zuzurechnenden Effekte ohne Kontrollgruppe analysiert 
werden können. In den prospektiven einarmigen Studien traten bei zwei von 
insgesamt 161 PatientInnen (1,2 %), die das Follow-Up durchliefen, verfah-
rensbezogene unerwünschte Ereignisse auf. 
Die am häufigsten berichteten unerwünschten Ereignisse waren Kongestion 
der Haut in drei PatientInnen (23,1 %) nach der Behandlung mit VSLNT [22] 
und Hautreizungen an der Stelle der Kontrastmittelinjektion in zwei Patien-
ten (10 %) nach der Behandlung mit LVA [21]. 
Keine der Studien berichtete über nicht-verfahrensbezogene unerwünschte 
Ereignisse. 
Laufende Studien 
Aktuell sind drei laufende RCTs registriert, die möglicherweise einen Effekt 
der LVA mit einer höheren Evidenzqualität zeigen könnten: zwei RCTs eva-
luieren LVA im Vergleich zur komplexen physikalischen Entstauungsthera-
pie (NCT02790021 & JPRN-UMIN000025137) und eine laufende Pilotstudie, 
die die Wirksamkeit der Roboter-assistierten LVA mit der konventionellen 
LVA evaluiert (NTR6465). 
Darüber hinaus konnten acht weitere laufende Studien identifiziert werden: 
vier NRCTs und vier nicht-randomisierte einarmige Studien. 
Kostenerstattung 
In Österreich werden die Kosten der LVA zur Behandlung von Lymphödemen 
derzeit nicht erstattet. 
 
Diskussion 
Das Ziel des vorliegenden Berichts war es, die klinische Wirksamkeit und 
Sicherheit der LVA im Vergleich zu der Vergleichsgruppe (z. B. VLNT) für 
die Behandlung von Lymphödemen zu bewerten. Insgesamt kann die Stärke 
der Evidenz für die klinische Wirksamkeit und Sicherheit als „sehr gering“ 
eingestuft werden, aufgrund von hohem Bias-Risiko in der NRCT, einge-
schlossenen Beobachtungsstudien, mangelhafte Ergebnisberichte und gerin-
gen Anzahl an PatientInnen. 
Das Biasrisiko wurde als moderat bis hoch eingestuft, da keine Randomisie-
rung oder Verblindung durchgeführt wurde, sowie aufgrund unzureichender 
Berichterstattung über kritische Ergebnisse (z. B. QoL), unklarem Berichten 
von Störvariablen und die konsekutive Rekrutierung von PatientInnen. 
kritischer Endpunkt 
unerwünschte 
Ereignisse: 
in NRCT keine 
unerwünschten 
Ereignisse mit LVA;  
mit VSLNT 3 von  
13 PatientInnen (23.1 %) 
 
in prospektiven Studien: 
2 von insgesamt  
161 PatientInnen (1.2 %) 
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unerwünschtes Ereignis: 
LVA: Hautirritationen 
nach Kontrastmittel-
injektion (n=2); 
VSLNT: Kongestion der 
Haut (n=3); 
3 laufende RCTs 
8 weitere laufende 
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Stärke der Evidenz für 
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und Sicherheit  
sehr gering 
moderates bis  
hohes Biasrisiko 
Zusammenfassung 
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In Anbetracht der Ergebnisse der eingeschlossenen Studien zeigen sich un-
terschiedliche Ergebnisse nach einer LVA. Darüber hinaus variiert die Qua-
lität dieser Studien. Wesentlicher Kritikpunkt der meisten identifizierten 
prospektiven einarmigen Studien ist die geringe Anzahl eingeschlossener Pa-
tientInnen. Zur Identifikation von seltenen unerwünschten Ereignissen könn-
te die kleine Fallzahl unzureichend sein. Ein weiterer essentieller Kritikpunkt 
sind die relativ kurzen Nachbeobachtungszeiträume in den einzelnen Studien. 
Lediglich eine Studie hatte einen Nachbeobachtungszeitraum von mehr als 
12 Monaten [20]. Daher fehlen zuverlässige Daten über die längerfristigen 
Sicherheits- und Wirksamkeitsergebnisse. Ein weiterer Kritikpunkt dieses Be-
richts besteht darin, dass die eingeschlossenen Studien hinsichtlich der Sta-
dien des Lymphödems, der Lokalisation des Lymphödems (obere oder untere 
Extremität) unterschiedlich waren und die Ergebnisse der primären und se-
kundären Lymphödeme nicht getrennt berichtet wurden, was zu Abweichun-
gen der Wirksamkeit und Sicherheit der Ergebnisse führen kann. 
Nichtsdestotrotz scheint eine LVA für die Behandlung von primärem und se-
kundärem Lymphödem sicher zu sein. Jedoch konnte keine Evidenz aus kon-
trollierten Studien für entscheidende Endpunkte identifiziert werden, die die 
LVA mit einem Komparator vergleicht. PatientInnenrelevante Endpunkte wie 
QoL wurden nur in den prospektiven einarmigen Studien beschrieben und 
inkonsistent berichtet (z. B. unterschiedliche Messskalen). Da die eingeschlos-
senen Studien eine schlechte Evidenzqualität und ein hohes Verzerrungspo-
tenzial aufweisen, ist es nicht möglich, eine verlässliche Aussage zur klini-
schen Wirksamkeit der LVA zu ziehen. 
Zukünftige RCTs und/oder prospektive NRCTs müssen durchgeführt wer-
den, um den optimalen Algorithmus zur Behandlung des Lymphödems zu 
finden und um die genaue PatientInnengruppe zu bestimmen, die am meis-
ten von dem Verfahren profitieren würde. Darüber hinaus sollten diese Stu-
dien durchgeführt werden, um die Ergebnisse, insbesondere im Hinblick auf 
QoL, zu bestätigen und weitere Kenntnisse in diesem Bereich zu erlangen. 
 
Empfehlung 
Auf der Grundlage der verfügbaren Evidenz können keine Schlussfolgerun-
gen gezogen werden, ob das bewertete Verfahren der LVA mindestens gleich 
wirksam und sicherer ist wie die Vergleichsbehandlung mit VLNT. Aufgrund 
der methodischen Mängel der vorliegenden Evidenz (lediglich ein wichtiges 
Ergebnis, aber nicht entscheidend für die Empfehlung, wurde in dem einzi-
gen NRCT berichtet), können keine Rückschlüsse auf die Wirksamkeit des 
Verfahrens gezogen werden. Qualitativ hochwertige Studien sind aufgrund 
konsistenter positiver Befunde, die auf Beobachtungsdaten in Bezug auf die 
Volumenreduktion der Extremitäten basieren, erforderlich. Hinsichtlich der 
Sicherheitsergebnisse wurden nur verfahrensbedingte Komplikationen auf 
der Grundlage von Daten aus einem NRCT und vier prospektiven einarmi-
gen Studien berichtet, die auf ein relativ sicheres LVA-Profil hindeuten. Neue 
Studienergebnisse, die auf einem qualitativ hochwertigen RCT basieren, 
könnten die Effektschätzung erheblich beeinflussen. 
Eine Re-Evaluierung wird nach 2021 empfohlen, wenn die potenziell relevan-
ten laufenden Studien abgeschlossen sind und lediglich wenn patientInnen-
relevante Endpunkte zur Ableitung einer Empfehlung einbezogen werden. 
Ansonsten können nach wie vor keine Aussagen zu patientInnenrelevanten 
Endpunkten getroffen werden. 
Studien zeigen 
unterschiedliche 
Ergebnisse und Qualität 
ist niedrig 
LVA könnte sicheres 
Verfahren sein, aber 
niedrige Evidenzqualität 
 verlässliche Aussage 
zur klinischen 
Wirksamkeit  
nicht möglich 
weitere hochwertige 
Studien notwendig, um 
Ergebnisse zu bestätigen 
(z. B. QoL) und jene 
PatientInnen zu 
erreichen, die am 
meisten von dem 
Verfahren profitieren 
Evidenz unzureichend 
 LVA derzeit nicht 
empfohlen 
Re-Evaluierung nach 
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patientInnenrelevante 
Endpunkte beinhalten 
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1 Scope 
1.1 PICO question 
Is lymphovenous anastomosis in comparison to conservative or other surgi-
cal treatments (e.g., lymph node transfer/transplantation) in patients with 
lymphoedema stage I, II and III more effective and safer concerning pain, 
functionality, quality of life (QoL), recurrence or complications? 
 
 
1.2 Inclusion criteria 
Inclusion criteria for relevant studies are summarized in Table 1-1. 
Table 1-1: Inclusion criteria 
Population Patients with primary or secondary lymphoedema stage I, II and III in whom a 
conservative treatment (e.g., CDT) is ineffective or does not lead to a substantial 
improvement of the lymphoedema. 
Lymphoedema is a swelling (oedema) that results from an accumulation of protein-rich 
fluid in the interstitial space because of congenital or acquired damage to the lymphatic 
system (lymph vessels or lymph nodes). 
ICD-10 codes: 
I89.0- Lymphoedema, not elsewhere classified 
I89.8 Other specified noninfective disorders of lymphatic vessels and lymph nodes 
I89.9 Noninfective disorder of lymphatic vessels and lymph nodes, unspecified 
I97.2- Postmastectomy lymphoedema syndrome 
MeSH-terms: Lymphoedema (Breast Cancer Lymphoedema, Non-Filarial Lymphoedema) 
Intervention Lymphovenous/lymphaticovenous/lymphaticovenular anastomosis (LVA) 
Lymphovenous/lymphaticovenous/lymphaticovenular bypass 
The procedure is a microsurgical/supermicrosurgical technique, where a surgical union  
or shunt between ducts, tubes, or vessels is made. It may be end-to-end, end-to-side,  
side-to-end, or side-to-side. 
MeSH term: Anastomosis, Surgical; No MeSH terms for  
lymphovenous/lymphaticovenous available. 
Control Conservative or other surgical treatments (vascularized lymph node transfer/ 
transplantation [VLNT]). 
Outcomes  
Efficacy Clinical endpoints: 
 Quality of Life 
 Functionality (retain or restore function, range of joint motion) 
 Pain (alleviate pain & discomfort) 
 Recurrence 
Surrogate endpoints: 
 Limb volume reduction (limb circumference, intra-/extracellular fluids) 
Safety  Complications (e.g., infection, lymphorrhea) 
 Adverse events, procedure-related (e.g., infection, additional procedure, re-exploration) 
 Adverse events, procedure unrelated 
 
PIKO-Frage 
Einschlusskriterien  
für relevante Studien 
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Study design  
Efficacy Randomised controlled trials 
Prospective non-randomised controlled trials 
Safety Randomised controlled trials 
Prospective non-randomised controlled trials 
Prospective case-series (n ≥ 10 patients) 
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2 Methods 
2.1 Research questions 
Description of the technology 
Element ID Research question 
B0001 What is lymphovenous anastomosis? 
B0002 What is the claimed benefit of lymphovenous anastomosis in relation to the comparators? 
B0003 What is the phase of development and implementation of lymphovenous anastomosis? 
B0004 Who administers lymphovenous anastomosis and the comparators and in what context  
and level of care are they provided? 
B0008 What kind of special premises are needed to use lymphovenous anastomosis and the 
comparator(s)? 
B0009 What supplies are needed to use lymphovenous anastomosis and the comparator(s)? 
A0020 For which indications has lymphovenous anastomosis received marketing authorisation  
or CE marking? 
A0021 What is the reimbursement status of lymphovenous anastomosis? 
 
Health problem and Current Use 
Element ID Research question 
A0001 For which health conditions, and for what purposes is lymphovenous anastomosis used? 
A0002 What is the disease or health condition in the scope of this assessment? 
A0003 What are the known risk factors for the disease or health condition? 
A0004 What is the natural course of the disease or health condition? 
A0005 What is the burden of disease for the patients with the disease or health condition? 
A0006 What are the consequences of the disease or health condition for the society? 
A0024 How is the disease or health condition currently diagnosed according to published guidelines 
and in practice? 
A0025 How is the disease or health condition currently managed according to published guidelines 
and in practice? 
A0007 What is the target population in this assessment?  
A0023 How many people belong to the target population? 
A0011 How much are lymphovenous anastomosis utilised? 
 
Clinical Effectiveness 
Element ID Research question 
D0005 How does lymphovenous anastomosis affect symptoms and findings (severity, frequency)  
of the disease or health condition? 
D0006 How does lymphovenous anastomosis affect progression (or recurrence) of the disease  
or health condition? 
D0011 What is the effect of lymphovenous anastomosis on patients’ body functions? 
D0016 How does the use of lymphovenous anastomosis affect activities of daily living? 
D0012 What is the effect of lymphovenous anastomosis on generic health-related quality of life? 
D0013 What is the effect of lymphovenous anastomosis on disease-specific quality of life? 
D0017 Was the use of lymphovenous anastomosis worthwhile? 
D0001 What is the expected beneficial effect of lymphovenous anastomosis on mortality? 
D0003 What is the effect of lymphovenous anastomosis on the mortality due to causes other than 
the target disease? 
 
Lymphovenous anastomoses in patients with primary and secondary lymphoedema 
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Safety 
Element ID Research question 
C0008 How safe is lymphovenous anastomosis in comparison to the comparator(s)? 
C0002 Are the harms related to dosage or frequency of applying lymphovenous anastomosis? 
C0004 How does the frequency or severity of harms change over time or in different settings? 
C0005 What are the susceptible patient groups that are more likely to be harmed through the use of 
lymphovenous anastomosis? 
C0007 Are lymphovenous anastomosis and comparator(s) associated with user-dependent harms? 
B0010 What kind of data/records and/or registry is needed to monitor the use of lymphovenous 
anastomosis and the comparator? 
 
 
2.2 Sources 
Description of the technology 
 Handsearch in the POP, AdHopHTA, and CRD databases for Health 
Technology Assessments, and in Google 
 Background publications identified in database search: see Section 2.3 
 Questionnaire completed by the submitting hospitals 
Health problem and Current Use 
 Handsearch in the UpToDate database, POP, AdHopHTA, and CRD 
databases for Health Technology Assessments and in Google 
 Background publications identified in database search: see Section 2.3 
 Questionnaire completed by the submitting hospitals 
 Handsearch for management guidelines in the National Guideline 
Clearinghouse and in the database of the Arbeitsgemeinschaft der 
Wissenschaftlichen Medizinischen Fachgesellschaften e.V. (AWMF) 
 
  
Quellen: 
systematische Suche, 
Handsuche sowie 
Informationen des 
einreichenden 
Krankenhauses 
Methods 
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2.3 Systematic literature search 
The systematic literature search was conducted on the 14th of December 2017 
in the following databases: 
 Medline via Ovid (including PubMed) 
 Embase 
 The Cochrane Library 
 CRD (DARE, NHS-EED, HTA) 
The systematic search was not limited to years, but it was limited to articles 
published in English or German and to only prospective or randomized con-
trolled trials. After deduplication, overall 628 citations were included. The 
specific search strategy employed can be found in the Appendix (Chapter 
“Literature search strategies”). 
The submitting hospital sent 7 publications of which 0 new citations were 
identified. 
By hand-search, one additional article was found, resulting in overall 629 hits. 
A total of 14 systematic reviews and health technology assessments (HTAs) 
on lymphovenous anastomosis (LVA) could be identified through the system-
atic literature search. However, due to methodological differences (e.g., other 
study purposes, inclusion of retrospective studies) of the reviews, we decided 
to exclude the systematic reviews and HTAs from our analysis. Nonetheless, 
we searched through the reviews to see if they identified studies that we did 
not find via our systematic literature search. Most of these provided relevant 
background information for this report but no additional studies were iden-
tified. 
Furthermore, to identify ongoing and unpublished studies, a search in three 
clinical trials registries (ClinicalTrials.gov; WHO-ICTRP; EU Clinical Tri-
als) was conducted on the 09.01.2018 resulting in 15 hits. Of those 15 hits, 11 
were identified as potentially relevant trials and included in the Appendix 
(see Chapter “List of ongoing trials”). The other four ongoing trials were ex-
cluded because of other study aims or different scopes of application of LVA. 
 
  
systematische 
Literatursuche in vier 
Datenbanken 
insgesamt 629 
Publikationen 
identifiziert 
Suche nach  
laufenden Studien 
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2.4 Flow chart of study selection 
Overall 629 hits were identified. The references were screened by two inde-
pendent researchers (KR, MS) and in case of disagreement, a third research-
er was involved to solve the differences. The selection process is displayed in 
Figure 2-1. 
 
* Systematic reviews were excluded if they had other aims, included retrospective studies, compared surgical methods without 
patient outcomes, or were written in another language. 
** 1 publication presented sub-analytical results of another already included observational study. Therefore, only the overall data 
of the primary study are presented in the outcomes. 
Figure 2-1: Flow chart of study selection (PRISMA Flow Diagram) 
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2.5 Analysis 
The data retrieved from the selected studies (see Chapter 2.4) were systemat-
ically extracted into a data-extraction-table (see Appendix Table A-1 and Ta-
ble A-2). No further data processing (e.g., indirect comparison) was applied. 
The studies were systematically assessed for quality and risk of bias (RoB) by 
two independent researchers (KR, MS) using the risk of bias assessment tool 
for non-randomized controlled studies (RoBANS) [26] and the IHE Risk of 
Bias checklist for case series [27] presented in the Appendix (see Table A-3 
and Table A-4). 
 
 
2.6 Synthesis 
Based on the data-extraction-table (see Appendix Table A-1 and Table A-2), 
data on each selected outcome category were synthesised across studies ac-
cording to GRADE (Grading of Recommendations Assessment, Development 
and Evaluation) [28]. The research questions were answered in plain text for-
mat with reference to GRADE evidence tables that are included in the Ap-
pendix, results were summarized in Table 7-1. 
 
 
Datenextraktion  
und Bewertung  
des Bias-Risikos laut 
RoBANS & IHE Checkliste 
Evidenzsynthese  
mittels GRADE 
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3 Description and technical 
characteristics of technology 
Features of the technology and comparators 
B0001 – What is lymphovenous anastomosis? 
LVA is the focus of this report and aims to anastomose distal subdermal lym-
phatic vessels and adjacent venules with the diameter of less than 0.8 mm (it is 
difficult to find larger lymphatic vessels because most are 0.8 mm or under 
in diameter) [13, 14]. Early stage lymphoedema normally may not affect dis-
tal subdermal lymphatic vessels, so those are more readily available for a sur-
gical procedure than deeper lymphatic vessels [8, 13]. Further, blood pressure 
is lower in subdermal venules than in deeper, larger veins. It is very important 
that the pressure in the lymphatic vessel is higher than in the recipient ven-
ule to allow the lymphatic fluid to enter the venous bloodstream through the 
LVA procedure. Therefore, utilizing small venules as recipient vessels might 
lower the risk of obstruction of the LVA due to the backflow of the vein [8, 
13]. Hence, a smaller amount of venous backflow in subdermal vessels can be 
reported and may probably result in an ongoing improvement of lymphoe-
dema [13]. 
The aim of LVA is to restore lymphatic circulation and bypass obstructions 
and destructions in lymphatics by constructing an alternative lymph drain-
age pathway [12]. Therefore, a connection of functioning lymphatic vessels 
and similarly sized subdermal venules is made to allow unidirectional flow 
of lymphatic fluid directly into the venous system, meaning that the lymph 
does not need to pass the damaged lymphatic area to return to the circulation 
[5, 15, 16]. In addition, with the intention to achieve a more permanent im-
provement of lymphoedema, subdermal venules should be used because the 
pressure is lower than that in the deep, larger veins resulting in less venous 
backflow [24, 25]. 
LVA can be performed in four basic ways: end-to-end (E-E; distal or proxi-
mal portion of a lymphatic vessel is anastomosed to the proximal portion of 
a venule), side-to-side (S-S; the side wall of a lymphatic vessel is anastomosed 
to the side wall of a venule), end-to-side (E-S; distal or proximal portion of a 
lymphatic vessel is anastomosed to the side wall of a venule), and side-to-end 
(S-E; proximal portion of a venule is anastomosed to the side wall of a lym-
phatic vessel) (Figure 3-1) [17, 18]. These formations allow the establishment 
of unidirectional lymph flow from the distal limb of the lymphatic collector. 
Additionally, to the basic four types of LVAs, there are several other (ad-
vanced) methods described in the literature – like the π-shaped LVA or the 
“octopus”-LVA. The difference to the basic LVA methods is merely the ad-
ditional anastomosis of the lymphatic vessel to the venule [25, 29]. 
  
LVA ist supermikro-
chirurgische Methode, 
die distale subdermale 
Lymphgefäße und 
benachbarte Venolen 
mit einem Durchmesser 
von < 0,8 mm 
anastomosiert 
 
Blutdruck ist niedriger 
in subdermalen Gefäßen 
 venöser Rückfluss in 
Gefäße geringer 
Ziel der LVA ist die 
Wiederherstellung  
des lymphatischen 
Kreislaufs und die 
Umgehung von 
Hindernissen in 
Lymphgefäßen,  
indem ein alternativer 
Lymphdrainageweg 
konstruiert wird 
LVA kann end-zu-end, 
seit-zu-seit, seit-zu-end 
und end-zu-seit, wobei 
end-zu-end die 
einfachste Methode zu 
sein scheint 
darüber hinaus gibt es 
noch weitere andere/ 
weiterentwickelte  
LVA Arten  
(z. B. π-shaped LVA) 
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Figure 3-1: 
Basic four types of LVA (Source: [17]) 
B0002 – What is the claimed benefit of  
lymphovenous anastomosis in relation to the comparators? 
Supermicrosurgical techniques such as LVA aim to redirect the lymphatic flu-
id into venous circulation and to restore lymphatic drainage. They are a min-
imally invasive method to reconstruct the lymphatic pathway, and require less 
use of compression therapy postoperatively. Furthermore, LVA can potential-
ly provide a more permanent solution to chronic lymphoedema [2, 16, 30]. 
According to the information provided by the submitting hospital and the lit-
erature, LVA in lymphoedema may lead to a significant improvement in func-
tionality, prevention of the progressive fibrosis of the tissue, and lesser suscep-
tibility to infections (erysipelas, phlegmon, necrotizing fasciitis). Therefore, 
it may lead to reduction in the complication rate, shortened length of hospi-
tal stay, and shorter treatment duration (no further treatment with conserva-
tive treatment or compression therapy [use of compression garments] is nec-
essary). For the reasons above, an increased quality of life (QoL) and func-
tionality may be recorded [1, 5]. 
Since its development, the procedure has gained popularity because of its 
minimal invasiveness, better aesthetic outcome, and lower costs in compari-
son to physical medicine (e.g., lower [personnel] expenditures) [2, 31]. 
B0003 – What is the phase of development  
and implementation of lymphovenous anastomosis? 
Supermicrosurgical techniques such as LVA are used with satisfactory results 
since the first description of the technique for lymphoedema in the late ‘90s 
by Koshima [21, 32]. 
 
Administration, Investments, personnel and  
tools required to use the technology and the comparator(s) 
B0004 – Who administers lymphovenous anastomosis and  
in what context and level of care are they provided? 
B0008 – What kind of special premises  
are needed to use lymphovenous anastomosis? 
B0009 – What supplies are needed to use lymphovenous anastomosis? 
According to the information received by the submitting hospital, LVA is a 
supermicrosurgical procedure in which an outflow-obstructed lymphatic ves-
sel with a diameter of >0.1 and under 0.8 mm is microsurgically attached to 
a superficial small vein. As most lymphatics range from 0.1 to 0.6 mm in dia-
meter, supermicrosurgical techniques are required [33]. On that basis, the 
lymph can be removed via the venule and the swelling of the affected area de-
creases. 
LVA ist weniger invasiv, 
scheint bessere 
ästhetische Ergebnisse 
zu erzielen, weniger 
Komplikationen, kürzere 
Krankenhausaufenthalte 
und Behandlungsdauer, 
sowie geringere 
Notwendigkeit einer 
nachfolgenden 
Kompressionstherapie 
Verfahren seit 90er 
Jahre in Anwendung 
Lymphgefäße haben 
meist einen Durchmesser 
von >0,1 bis 0,6 mm  
supermikrochirurgische 
Techniken sind 
notwendig 
Description and technical characteristics of technology 
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The procedure is technically demanding, time-consuming, and requires a spe-
cialized team with experience in microsurgical techniques [19]. Thus, LVA is 
performed in institutions with trained personnel in both (super-)microsur-
gery and lymphology and with appropriate infrastructure. The utilization of 
appropriate imaging tools to document efficacy is necessary. If performed ear-
ly in the course of lymphoedema before damage to the lymphatic wall and 
impaired lymphatic contractility have occurred, it is suggested that there is a 
greater and longer lasting benefit [15]. 
In general, microsurgical procedures are performed in local or general anaes-
thesia. In children, they need to be performed with special caution [21, 34]. 
The procedure is performed under microscope with maximum magnifica-
tion and therefore, specifically designed supermicrosurgical instruments as 
well as suture material with the size of 11.0 and 12.0 are required. 
Further, to map healthy and functioning lymphatic vessels and to approve 
the patency of the anastomosis, one recent technological advance in LVA pro-
cedures is the use of indocyanine green (ICG) fluorescence lymphangiography 
[20]. After ICG dye is injected and has been absorbed by the lymphatic ves-
sels, fluorescence lymphangiography identifies the near-infrared light emitted 
by ICG dye and so illustrates the path of the lymphatic vessels and enables 
surgeons to locate and make incisions precisely over functioning lymphatics. 
Ongoing anastomosis patency can be confirmed during follow-up with lym-
phoscintigraphy or ICG lymphography. This additional ICG procedure, more 
precise microscopes, and optimal patient selection make the LVA procedure 
less invasive, may reduce operating time substantially, and improve the out-
come of LVA procedures [16, 20, 21]. 
 
Regulatory & reimbursement status 
A0020 – For which indications has lymphovenous anastomosis  
received marketing authorisation or CE marking? 
Since lymphovenous anastomosis is a procedure, no marketing authorisation 
or CE marking can be assigned. 
A0021 – What is the reimbursement status of lymphovenous anastomosis? 
Currently, lymphovenous anastomosis for lymphoedema is not included in 
the Austrian DRG-system (Leistungsorientierte Krankenanstaltenfinanzier-
ung/LKF). Therefore, the procedure itself is not reimbursed by the Austrian 
health care system. 
 
Verfahren erfordert 
spezialisiertes Team  
mit Erfahrung in 
mikrochirurgischen 
Techniken und 
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entsprechende 
Infrastruktur 
LVA wird unter lokaler 
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weiterer technischer 
Fortschritt ist 
Anwendung von  
ICG Lymphographie 
keine CE-Zertifizierung, 
da LVA ein Verfahren ist 
Verfahren wird in 
Österreich derzeit  
nicht erstattet 
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4 Health Problem and Current Use 
Overview of the disease or health condition 
A0001 – For which health conditions, and for what purposes  
is lymphovenous anastomosis used? 
According to the guideline of the Association of the Scientific Medical Socie-
ties in Germany (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen 
Fachgesellschaften e.V., AWMF) “S2k guideline for the diagnosis and therapy of 
lymphoedema” (S2k Leitlinie – Diagnostik und Therapie der Lymphödeme)1, 
LVA can be used as a surgical treatment option for primary and secondary 
lymphoedemas, if no additional venous outflow obstruction is present [1]. Ac-
cording to the submitting hospital, LVA is used for patients with peripheral 
primary or secondary lymphoedema of all entities and in whom a conservative 
treatment has failed. Further, the pump function of the lymphatic vessels has 
to be maintained as a mandatory requirement for the transaction of LVA. 
Appropriate patients for lymphatic reconstruction like LVA are less frequent-
ly found among patients with primary lymphoedema, due to variations in 
lymphatics and lymph nodes. In this situation, it could be possible that the 
majority of primary lymphoedema patients have a clinical manifestation of a 
developmental defect. Further, difficulties with LVAs occur if primary lym-
phoedema involves the lymphatic vessel (e.g., aplasia, hypoplasia) [19]. 
Patients with secondary lymphoedema often have a surgically correctable le-
sion along the major lymphatics; hence, immediate and long-term results may 
often be better in these patients. LVA seems to be a good option to restore 
normal lymphatic function in secondary lymphoedema due to cancer surgery 
and/or radiation therapy. In this condition, the lymph nodes have a selective 
damage and the distal lymph-collecting vessels remain intact [19]. 
Furthermore, LVA seems to be more effective in early stages of lymphoedema 
because functional lymphatics remain and minimal fibroadipose deposition 
occurs [19, 35]. 
Supermicrosurgical LVA is usually performed under general or local anaes-
thesia with minimal invasion, thus it is possible for high-risk patients (e.g., 
elderly patients and those with cardiopulmonary diseases or terminal cancer) 
to undergo the procedure [3, 36]. 
Indications for performing surgical treatment options are, besides others, in-
tractable pain, insufficient lymphoedema reduction, recurrent episodes of lym-
phangitis, decreasing limb function, patient dissatisfaction with conservative 
methods, the patients’ wish to proceed to surgery, and quality of life and psy-
chosocial burden [16]. 
Surgical methods, such as LVA, should not be carried out if a malignant lym-
phoedema2 and an internal/anesthesiological contraindication are present [1]. 
                                                             
1 Diagnostic guideline; S2k = guideline based on formal consensus finding. 
2 Florid, malignant diseases causing lymphoedema, lead to a progressive deterioration 
of lymphatic transport. Such an increasing reduction in lymphatic transport would 
counteract any operational measures aimed at increasing this transport performance. 
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A0002 – What is the disease or health condition in the scope  
of this assessment? 
In the scope of this assessment, peripheral lymphoedema is the condition of 
interest. Lymphoedema is a chronic disease and requires treatment [1]. 
Overall, lymphoedema can be congenital or acquired, so-called: 
 primary lymphoedema, caused by a congenital abnormality  
or malfunction in the lymphatic system, and 
 secondary lymphoedema, acquired condition caused by defects to the 
lymphatic system, usually due to cancer treatment, infection, trauma, 
etc. [2-4]. 
Lymphoedema can occur at any age – in childhood, primary forms are more 
common [1]. Secondary lymphoedema is more frequent than primary lympho-
edema [16]. 
A0003 – What are the known risk factors for lymphoedema? 
The leading cause of lymphoedema in developed countries is mostly the con-
sequence of malignancies and its treatments. Especially breast cancer thera-
pies in the forms of radiotherapy and lymph node dissection are seen as the 
classic precursor of secondary lymphoedema [10, 16, 23]. 
Axillary lymph node dissection, radiation therapy to the axillary region, post-
operative seroma in the axillary region, and obesity are seen as further major 
risk factors for developing lymphoedemas [8]. 
A0004 – What is the natural course of lymphoedema? 
For patients who suffer from lymphoedema, the onset of the disease is varia-
ble [23]. A lymphoedema arises from a composition of protein-rich fluid in 
the interstitial space with initial symptoms of soft, pitting oedema in the af-
fected extremity. This can cause inflammation of tissues and a stimulation of 
fibrosis. The worsening of the lymphatic function further results in adipose 
deposition in the subcutaneous tissues. All these factors influence the lym-
phoedema which leads to a worsening of symptoms and progresses to a thick, 
fibrotic, fatty, oedematous, and painful extremity that debilitates patients’ dai-
ly activities [23]. 
There is no cure for lymphoedema [2, 5, 6]. It is a chronic, progressive, and 
debilitating condition caused by an affected lymphatic system. Without ap-
propriate management, lymphoedema may worsen causing pain and comprise 
body image disturbances, infections, restrictions in range of motion (function-
al impairment/restricted mobility), swelling, cellulitis, and a decrease in pa-
tients’ QoL with functional, aesthetic, and psychic repercussions (e.g., abil-
ity to work, feeling of tightness, heavy feeling, narrowness of clothing, shoes 
and jewellery, and skin alterations). It may also lead to irreversible changes 
like fibrosis or the excess of adipose tissue. These patient-reported symptoms 
can occur individually or in combination [1, 7-11]. 
Early lymphoedema management (diagnosis and treatment) is the main chal-
lenge for treatment since the progress of chronic lymphoedema will generate 
interstitial fibrosis and worsening of the lymphatic ducts and nodes [10]. 
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Effects of the disease or health condition  
on the individual and society 
A0005 – What is the burden of disease for patients with lymphoedema? 
Patients with lymphoedema are at high risk to suffer from recurrent celluli-
tis, limitation of function, deformity or disfigurement, pain, and diminished 
QoL including emotional and psychosocial distress [2, 13]. 
Furthermore, recurrent infections may be caused by progressive enlargement 
and lymphatic stasis and have been shown to significantly reduce the quality 
of life (QoL) of patients (e.g., pain and functionality). Lymphoedema consti-
tutes a major health problem because of its high prevalence, the associated 
work incapacity for affected patients, and the increase of health care costs [5, 
31]. 
A0006 – What are the consequences of lymphoedema for the society? 
It is assumed that on the basis of the fact that lymphoedemas will probably 
occur more often in the future due to cancer treatments, and due to the ag-
ing population, the incidence of lymphoedema will presumably increase over 
time [16, 37]. In Austria, 39,906 newly diagnosed cancer patients were record-
ed in 2015. Of those, 4,854 men were affected by prostate cancer and 5,390 
women by breast cancer, which are the leading cancers in men and women, 
respectively, and also the major risk factors for the incidence of extremity lym-
phoedema [38]. 
 
Current clinical management of the disease or health condition 
A0024 – How are lymphoedemas currently diagnosed according  
to published guidelines and in practice? 
No Austrian guidelines for the diagnosis (and treatment) of lymphoedema 
were identified. Though, the Austrian Lymph-Liga refers in its description 
of lymphoedemas to the guideline of the AWMF for “S2k guideline for the 
diagnosis and therapy of lymphoedema” (S2k Leitlinie – Diagnostik und 
Therapie der Lymphödeme) [1]. 
According to this guideline, the pillars of the baseline diagnostics of lym-
phoedemas are patient history, inspection, and palpation and should be per-
formed in this order. The patient history include specific lymphatic anam-
nesis of oedemas. The baseline diagnostics should allow a clinical assessment 
for aetiology, patient-reported outcome, stage, and location of lymphoedema. 
If the baseline diagnostics cannot provide a clear diagnosis, further diagnos-
tic procedures should be performed for clarification. Advanced diagnostics are 
used to verify oedema and/or to detect or rule out a morphological or func-
tional disorder of the lymphatic system as the cause of oedema, as well as to 
plan surgery and therapy monitoring. To proof the diagnosis of a lymphoede-
ma, different methods depending on the stage are possible (e.g., baseline di-
agnostics, indirect lymphangiography, ICG lymphography, computed tomo-
graphy, lymphoscintigraphy, etc.) [1]. 
The basis for early diagnosis and follow-up are, in addition to risk stratifica-
tion, pre- and post-interventional measurement methods such as volume and/ 
or circumference measurement [1]. 
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Staging of lymphoedema 
Lymphoedema is usually staged by monitoring the physical condition of the 
patients [4]. The most common staging systems used for lymphoedema are 
the International Society of Lymphology (ISL) and the Campisi staging sys-
tems [39] (see Table 4-1). Further staging systems are, for example, the Ko-
shima Staging System of Lymphoedema and the M.D. Anderson Lymphoe-
dema Classification based on ICG Lymphangiography [20]. 
Table 4-1: ISL and Campisi staging of lymphoedema 
ISL stage and description Campisi stage and description 
stage 0 
(latency stage, 
subclinical stage) 
 non-clinical apparent 
lymphoedema, but partly 
pathological lymphoscintigram; 
 swelling is not yet evident; 
 subtle alterations in tissue 
fluid/composition and changes 
in subjective symptoms; 
stage I, a a. “Latent” lymphoedema, without 
clinical evidence of oedema, but with 
impaired lymph transport capacity 
(provable by lymphoscintigraphy) and 
with initial immuno-histochemical 
alterations of lymph nodes, lymph 
vessels and extracellular matrix. 
stage I 
(spontaneously 
reversible) 
 oedema of soft texture; 
 elevating of affected parts 
reduces the swelling; 
 early accumulation of fluid 
relatively high in protein 
count which subsides with 
limb elevation; 
stage I, b b. “Initial” lymphoedema, totally or 
partially decreasing by rest and draining 
position, with worsening impairment of 
lymph transport capacity and of immuno-
histochemical alterations of lymph 
collectors, nodes, and extracellular 
matrix. 
stage II 
(not 
spontaneously 
reversible) 
 oedema with secondary  
tissue alterations; 
 elevating of affected parts 
does not or rarely eliminates 
the swelling; 
 pitting is manifest; 
stage II a. “Increasing” lymphoedema, with 
vanishing lymph transport capacity, 
relapsing lymphangitic attacks, 
fibroindurative skin changes, and 
developing disability. 
b. “Column shaped” limb fibrolympho-
edema, with lymphostatic skin changes, 
suppressed lymph transport capacity 
and worsening disability. 
stage III  distorting hard swelling, 
partly lobar form with typical 
skin alterations; 
 encompasses lymphostatic 
elephantiasis (pitting can be 
absent and trophic skin 
changes have developed). 
stage III a. Properly called “elephantiasis”,  
with scleroindurative pachydermitis, 
papillomatous lymphostatic verrucosis, 
no lymph transport capacity and  
life-threatening disability. 
b. “Extreme elephantiasis” with total 
disability. 
Sources: [1, 15, 39] 
 
A0025 – How are lymphoedemas currently managed according to 
published guidelines and in practice? 
The treatment of peripheral lymphoedema is divided into conservative (non-
surgical) and surgical [15]. Conservative treatment of primary and secondary 
lymphoedema comprises of compression techniques (including multilayer 
bandaging techniques, self-adherent wraps, and compression garments at pre-
scribed pressure gradients), intermittent pneumatic compression, complex 
decongestive therapy (CDT), manual lymphatic drainage, exercise, low-level 
laser, ultrasound, and aquatherapy [4]. 
am häufigsten 
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standard sind 
konservative Therapien 
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Currently, standard of care for the treatment of early lymphoedema are con-
servative therapy options. Conservative therapies aim to control symptoms by 
minimising fluid build-up, hence they are not curative, but delay the progres-
sion [2, 7, 8, 15, 35]. According to the submitting hospital, conservative ther-
apy has failed in controlling the progression of lymphoedema when, despite 
exhausting all measures of the CDT, there is no improvement or even wors-
ening of the symptoms [19]. If peripheral lymphoedema is refractory to con-
servative therapies, surgical methods (e.g., LVA) are becoming a treatment 
option [17]. 
According to the AWMF guideline for “S2k guideline for the diagnosis and 
therapy of lymphoedema” (S2k Leitlinie – Diagnostik und Therapie der 
Lymphödeme), surgical treatment should be considered if a patient has a bur-
den or an increase in secondary tissue changes despite guideline conservative 
therapy and adherence to therapy. When deciding on an operative method, 
the reconstruction of the interrupted lymphatic system or a deviating proce-
dure should be considered a priority [1]. 
Surgical approaches are classified as reductive (e.g., liposuction, skin/subcu-
taneous excision) or physiological (e.g., lymphovenous anastomosis [LVA], vas-
cularized lymph node transfer/transplantation [VLNT]) [5, 36]. Surgical ap-
proaches also include supermicrosurgical procedures. These supermicrosur-
gical procedures comprise of derivative methods (e.g., LVA) and reconstructive 
methods (sophisticated techniques which involve the use of a lymphatic col-
lector [LLA] or an interposition vein segment [LVLA] to restore lymphatic 
continuity in lymphoedema conditions) [15]. A stage-related and individual-
ly customised treatment modality has to be considered [1]. 
According to the guideline of the AWMF “S2k guideline for the diagnosis 
and therapy of lymphoedema” (S2k Leitlinie – Diagnostik und Therapie der 
Lymphödeme), surgical treatment should only be offered to adult patients 
with phase I and II lymphoedema after a guideline-compliant ambulatory 
and/or inpatient CDT for the period of at least six months [1]. In selected 
patients, a combination of LVA and VLNT procedures may be considered 
effective [40]. 
If the treatment of lymphoedema is in an advanced stage, the aim of the 
treatment is to return the lymphoedema to a lower lymphoedema stage [1]. 
 
Target population 
A0007 – What is the target population in this assessment? 
The target population in this assessment are patients with primary and sec-
ondary lymphoedema stage I and II in whom a conservative treatment (e.g., 
CDT) is ineffective or does not lead to a substantial improvement of the 
lymphoedema after the recommended conservative treatment period. 
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A0023 – How many people belong to the target population? 
According to the guideline of the AWMF for “S2k guideline for the diagno-
sis and therapy of lymphoedema” (S2k Leitlinie – Diagnostik und Therapie 
der Lymphödeme), the incidence of primary lymphoedema at birth is (esti-
mated) about 1: 6,000, with a prevalence of about 1: 87,000 among <20 year 
old patients. Exact data on the occurrence of secondary lymphoedema are 
difficult to determine. In industrialized countries, the incidence of secondary 
lymphoedema is estimated to be around 0.13-2%. Women are significantly 
more often affected (by primary lymphoedema) than men (male: female=1: 
4.5 to 1: 6.1). The number of people affected increases with age. According to 
the AWMF guideline, the incidence of lymphoedema 12-24 months after breast 
carcinoma after axillary lymph node removal is 19.9%; after sentinel node 
biopsy 5.6%. For gynaecological tumours, a lymphoedema incidence of ap-
proximately 20% is indicated after lymph node removal [1]. 
International studies report an incidence of lymphoedema that ranges from 
10% to 50%, depending on the treatment procedure and cancer type. Lympho-
edema after breast cancer treatment is the most common form with a varia-
tion of 24-49% following mastectomies and 4-28% following breast-conserv-
ing therapy [8, 11]. 
According to the “Yearbook of Health Statistics 2008” (Jahrbuch der Gesund-
heitsstatistik 2008) of Statistik Austria, there were 6 surgeries of patients with 
lymphoedema/elephantiasis recorded in 2008 [41]3. In 2016, Statistik Austria 
recorded 9,908 hospital stays due to operations on lymph nodes or lymphat-
ics [42].4 
Specific data for Austria on the actual number of patients affected by lym-
phoedema could not be identified. 
A0011 – How much is lymphovenous anastomosis  
in lymphoedema utilised? 
According to the information provided by the submitting hospital, the an-
nual frequency in this hospital (number of beds=~270) is estimated to be 30 
LVA procedures in lymphoedemas. The total estimations provided regarding 
the annual frequency in Austria is 100 LVA procedures. 
 
                                                             
3 No current data available. 
4 However, the number of hospital stays is not reported for indications separately. 
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5 Clinical effectiveness 
5.1 Outcomes 
LVA in lymphoedema is primarily used to reduce limb volume or circumfer-
ence reduction, hence reducing pain and cellulitis with the aim to improve pa-
tients’ QoL and functionality. LVA is not used for a curative treatment, hence 
the procedure does not influence patients’ survival. Therefore, this outcome 
was not listed as crucial or important for the recommendation. 
The following outcomes were defined as crucial to derive a recommendation: 
 Quality of life (QoL) 
 Pain 
 Functionality 
 Recurrence. 
Further outcomes were defined as important, but not crucial to derive a rec-
ommendation: 
 Limb volume or circumference reduction 
 
 
5.2 Included study 
To assess the clinical effectiveness of LVA in patients with lymphoedema, we 
only identified one non-randomized controlled study (NRCT) [22] with 43 
patients treated with LVA and 13 patients treated with vascularized supracla-
vicular lymph node transfer (VSLNT) for the lower extremities, respectively. 
Study characteristics 
The NRCT was conducted in Japan in a university hospital and a cancer 
centre [22]. The procedure was either performed side-to-end or end-to-end, 
and the operation time in lower extremity lymphoedema was reported in 
this study with a mean of 213 minutes. The diameter of lymphatic vessels in 
which LVAs were performed was not described in this study. 
The NRCT only included patients with advanced primary or secondary low-
er extremity lymphoedema, hence only patients with severe/advanced stages 
of lymphoedema, but had unclear reporting of lymphoedema staging classi-
fication [22]. In this NRCT, patients with early-stage lymphoedema were ex-
cluded. 
Patient characteristics 
The mean age of patients ranged from 54.1 years in the LVA group to 63.7 
years in the VSLNT group. The mean age was significantly lower in the LVA 
group. The female study participants were overrepresented in both groups 
ranging from 93.0 to 100%, respectively. 
The mean follow-up ranged from 15.1 months (VSLNT) to 18.3 months (LVA). 
No losses to follow-up were reported in the NRCT. 
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The underlying disease of secondary lymphoedema was assumingly cancer 
(lymph node dissection) and phlegmon in 52 patients, while no underlying 
disease was reported for four patients of the LVA group (probably primary 
lymphoedema). The mean duration of persistent lymphoedema was not re-
ported. 
All patients received supervised compression therapy for at least three months 
before surgery and ICG lymphography as pre-interventional procedures. Sim-
ple self-lymph drainage directly after discharge was used together with the 
occasional elastic garments until the final follow-up. No additional interven-
tions were performed. 
Study characteristics and results of the included study are displayed in Ta-
ble A-1 and in the evidence profile in Table A-6. 
 
 
5.3 Results 
Morbidity 
D0005 – How does lymphovenous anastomosis affect symptoms  
and findings (severity, frequency) of lymphoedema? 
No evidence was found on the two crucial outcomes pain and functionality. 
In the NRCT, changes in the postoperative volume were compared using the 
Lower Extremity Lymphoedema index (LEL). This index was calculated 
from the circumferences of 5 points on the limb (the superior edge of the pa-
tella, 10 cm above and below the patella, the lateral malleolus, and the dor-
sum of the foot) and the body mass index, which aimed to yield an accurate 
quantitative assessment of the severity of lymphoedema [22]. 
The mean changes of volume compared with preoperative volumes were in 
the LVA group 21.2 (±2.0) and in the VSLNT group 26.5 (±4.4) with statisti-
cal significance in favor of the VSLNT group. 
D0006 – How does lymphovenous anastomosis affect progression  
(or recurrence) of lymphoedema? 
No evidence was found on the crucial outcome remission. 
 
Function 
D0011 – What is the effect of lymphovenous anastomosis  
on patients’ body functions? 
No evidence was found to answer the research question. 
D0016 – How does the use of lymphovenous anastomosis  
affect activities of daily living? 
No evidence was found to answer the research question. 
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Eingriff eigenständige 
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keine Evidenz für 
kritische Outcomes 
Schmerz und 
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Veränderungen  
des postoperativen 
Volumens wurde mittels 
LEL Index erhoben 
 
statistisch signifikante 
Verbesserung der 
durchschnittlichen 
Volumensveränderung 
in VSLNT Gruppe 
keine Evidenz  
keine Evidenz 
keine Evidenz 
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Health-related quality of life 
D0012 – What is the effect of lymphovenous anastomosis  
on generic health-related quality of life? 
No evidence was found on the crucial outcome QoL. 
D0013 – What is the effect of lymphovenous anastomosis  
on disease-specific quality of life? 
No evidence was found to answer the research question. 
 
Patient satisfaction 
D0017 – Was the use of lymphovenous anastomosis worthwhile? 
No evidence was found to answer the research question. 
 
Mortality 
D0001 – What is the expected beneficial effect  
of lymphovenous anastomosis on mortality? 
No evidence was found to answer the research question 
D0003 – What is the effect of lymphovenous anastomosis  
on the mortality due to causes other than the target disease? 
No evidence was found to answer the research question. 
 
 
keine Evidenz  
keine Evidenz 
keine Evidenz 
keine Evidenz 
keine Evidenz 
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6 Safety 
6.1 Outcomes 
The following outcomes were defined as crucial to derive a recommendation: 
 Complications 
 Adverse events, procedure-related  
(e.g., infection, additional procedure, re-exploration) 
 Adverse events, procedure-unrelated (e.g., infection, lymphorrhea) 
In accordance with the European Commission guidelines for medical devic-
es5 on serious adverse event reporting, the following definition was applied: 
Procedure-related adverse events are complications that are associated with 
the surgical intervention. Possible procedure-related complications are events 
associated with anaesthesia, infections, damages to nerves or blood vessels, 
bleeding, or the occurrence of blood clots (e.g. thrombosis). 
 
 
6.2 Included Studies 
The study inclusion criteria for assessing safety differed from the ones for as-
sessing clinical effectiveness. In addition to NRCTs, prospective studies with-
out a control group (interventional single-arm studies, case series, and regis-
try studies), but with patient numbers of greater than or equal 10 patients, 
were considered for the assessment of safety. 
In order to assess safety-related outcomes of LVA in patients with lymphoe-
dema, we identified only one comparative study [22] with 43 patients treated 
with LVA and 13 patients with VSLNT. Patient and study characteristics are 
displayed in Chapter 5.2. 
Four prospective interventional single-arm, single-centre studies also met our 
inclusion criteria [3, 10, 20, 21] with a total of 161 patients6, for the assess-
ment of safety of LVA. In those studies, LVA was performed in the upper ex-
tremities in 150 patients and in lower extremities in 11 patients. 
Study characteristics 
The four prospective interventional single-arm studies were conducted in the 
US [20], Netherlands [3, 21], and France [10]. One study was supported by 
the Kyte Research and Education Fund and the National Institutes of Health 
through M.D. Anderson´s Cancer Center Support Grant [20]. Three studies 
did not report on funding [3, 10, 21]. 
                                                             
5 http://ec.europa.eu/consumers/sectors/medical-devices/files/meddev/2_7_3_en.pdf 
6 It is important to note that in the study of Chang 2013 [20] 100 patients are included, 
but the outcome data is only reported on 37 patients and the baseline data is reported 
on an unknown number of patients. We decided to report outcomes of this study, 
but consequently, data may be imprecise. 
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(siehe 5.2) 
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The procedure was either performed end-to-end or end-to-side [20], end-to-
side [3] or end-to-end [10]. One study did not report on the procedure mo-
dality of the performed LVA’s [21]. 
All of the studies were conducted in university hospitals or cancer centres, 
except for one that was conducted in a day surgery setting [10]. Mean opera-
tion time of upper extremity lymphoedema ranged from 60 to 240 minutes 
across studies. The operation time in lower extremity lymphoedema was not 
reported in one study [20]. The diameter of lymphatic vessels in which LVAs 
were performed was described in two studies with a mean of ≤0.3 mm [3] and 
0.2-1.0 mm [20]. The other three studies did not report on this procedure 
characteristic [10, 21, 22]. 
Inclusion criteria differed slightly between the included prospective interven-
tional single-arm studies. One study included all patients with secondary ex-
tremity lymphoedema [20]. No other inclusion criteria were set for this study. 
One study included only female patients over 18 years of age [10]. Across stud-
ies, patients were eligible for inclusion if they had lymphoedema for more 
than 12 months, absence of skin infections, no response to physiotherapy or 
complex decongestive therapy for a minimum of three months, and lympho-
edema secondary to breast cancer [3, 10, 21]. 
All of the studies included patients with moderate and severe lymphoedema 
stages. The staging of lymphoedema was reported with ISL [21] or Campisi 
staging [3]; the other studies had unclear reporting of lymphoedema staging 
or did not report this characteristics. 
Exclusion criteria were only reported in one study: one prospective interven-
tional single-arm study excluded patients if they were not treated with pre-
vious physiotherapy for lymphoedema or if they refused to sign the informed 
consent [10]. 
For detailed information see Appendix (Table A-1 and Table A-2). 
Patient characteristics 
The mean age of patients ranged from 54 to 64 years across trials. The female 
study participants were overrepresented in all (100%), but one study. This 
study did not report on the gender of included patients [20]. 
The mean follow-up of the studies ranged from 7.8 [21] to 30.4 months [20]. 
One study reported no losses to follow-up [3], while two other studies had 
unclear reporting of loss to follow-up [10, 21], and one study did not report 
loss to follow-up [20]. 
The mean duration of persistent lymphoedema was 3.5 to 6.6 years across 
studies. One study did not report on the mean duration of lymphoedema in 
their patient group [10]. 
The underlying diseases causing lymphoedema were breast cancer in 150 pa-
tients [3, 10, 20, 21], sarcoma in three patients, melanoma in two patients, 
and gynaecologic cancer in six patients [20], respectively. Skin infection was 
additionally reported with breast cancer in five patients in one study [21]. 
Pre-interventional procedures comprised of ICG lymphography in two stud-
ies [20, 21], and standardized conservative treatment for three months and 
perioperative usage of antibiotics in another study [3]. The fourth study did 
not report on pre-interventional procedures [10]. 
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Compression bandages and elevation of affected limb were performed as post-
interventional procedures in two studies [3, 20]. Further procedures were re-
moval of the sleeve and lymphatic drainage physiotherapy beginning two 
weeks post-surgery [10], prophylactic intravenous antibiotics and compres-
sion garments four weeks post-surgery [20], and elastic stockings during fol-
low-up [3]. One study did not report on post-interventional procedures [21]. 
Additional interventions were only reported in one study: VLNT was per-
formed due to no improvement of lymphoedema after an LVA in one patient 
[20]. 
Study characteristics and results of included studies are displayed in Table 
A-1 and Table A-2 and in the evidence profile in Table A-6. 
 
 
6.3 Results 
Patient safety 
C0008 – How safe is lymphovenous anastomosis  
in comparison to the comparator(s)? 
Only one NRCT could be identified and reported procedure-related adverse 
events [22]. In the LVA group of this study, no adverse events were reported 
compared to the VSLNT group, where adverse events were reported in three 
patients who completed the follow-up, out of 13 patients (23.1%), with sta-
tistical significance in favor of LVA. 
Procedure-related complications of prospective interventional single-arm 
studies can also be considered for the analysis of safety because the effects 
directly attributable to the procedure can be analyzed without a control 
group. In these studies, adverse events occurred in two patients who com-
pleted the follow-up, out of 161 included patients across these studies 
(1.2%). 
Adverse events, procedure related 
The most frequent adverse events reported were congestion to the skin pad-
dle in three patients (23.1%) after the treatment with VSLNT [22], and skin 
irritation at the site of contrast injection in two patients (10%) after the treat-
ment with LVA [21]. 
Two studies did not report any procedure related adverse events for the treat-
ment with LVA [10, 20]. 
One study did not report on procedure-related adverse events for LVA [3]. 
Adverse events, procedure unrelated 
None of the studies reported on procedure unrelated adverse events. 
C0002 – Are the harms related to dosage or frequency of applying 
lymphovenous anastomosis? 
No evidence was found to answer the research question. 
nach dem Eingriff: 
Kompressionsbandagen, 
Lymphdrainage, 
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von Antibiotika und 
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in prospektiven Studien: 
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161 PatientInnen (1.2 %) 
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C0004 – How does the frequency or severity  
of harms change over time or in different settings? 
No evidence was found to answer the research question. 
C0005 – What are the susceptible patient groups that are more likely  
to be harmed through the use of lymphovenous anastomosis? 
No evidence was found to answer the research question. 
C0007 – Are lymphovenous anastomosis and comparator(s) associated 
with user-dependent harms? 
No evidence was found to answer the research question. 
 
Investments and tools required 
B0010 – What kind of data/records and/or registry is needed  
to monitor the use of lymphovenous anastomosis and the comparator? 
No evidence was found to answer the research question. 
 
 
keine Evidenz 
keine Evidenz 
keine Evidenz 
keine Evidenz 
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7 Quality of evidence 
RoB for individual studies was assessed with the IHE checklist for case se-
ries [27] and with the RoBANS risk of bias assessment tool for non-random-
ized controlled studies [26] and is presented in Table A-3 and Table A-4 in 
the Appendix. 
The NRCT was graded with a moderate to high RoB, although the tool is not 
intended to produce an overall rating. The reasons for downgrading were no 
randomization, unclear reporting of confounding variables, no blinding of 
outcome assessors, and no reporting on critical outcomes (e.g., QoL, pain). Re-
garding the four case series, two were assessed with a moderate RoB and two 
with a high RoB, due to unclear reporting of study design and study charac-
teristics, no reporting on staging of lymphoedema, insufficient reporting on 
QoL, discrepancy in patient numbers for loss to follow-up, and unclear report-
ing on competing interests and sources of support. 
The strength of evidence was rated according to GRADE (Grading of Recom-
mendations Assessment, Development and Evaluation) scheme [28] for each 
endpoint individually. Each study was rated by two independent researchers. 
In case of disagreement, a third researcher was involved to solve the differ-
ence. A more detailed list of criteria applied can be found in the recommen-
dations of the GRADE Working Group [28]. 
GRADE uses four categories to rank the strength of evidence: 
 High = We are very confident that the true effect lies close to that of 
the estimate of the effect;  
 Moderate = We are moderately confident in the effect estimate: the 
true effect is likely to be close to the estimate of the effect, but there 
is a possibility that it is substantially different;  
 Low = Our confidence in the effect estimate is limited: the true effect 
may be substantially different from the estimate of the effect;  
 Very low = Evidence either is unavailable or does not permit  
a conclusion. 
The ranking according to the GRADE scheme for the research question can 
be found in the summary of findings table below and in the evidence profile 
in Appendix Table A-6. 
Overall, the strength of evidence for the effectiveness and safety of LVA is 
very low. 
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Table 7-1: Summary of findings table of LVA 
Outcomes 
Anticipated absolute effects* (95% CI) 
Relative effect 
(95% CI) 
№ of participants  
(studies) 
Certainty of the 
evidence 
(GRADE) 
Comments 
Risk with VSLNT Risk with LVA 
Mean changes of volume 
compared with preoperative 
volume measurements 
follow up: mean 15.1-18.3 months  
Improvement value of LEL index: 
LVA: 21.2 (+-2.0) vs. VSLNT: 26.5 (+-4.4), 
s.s. 
- 56 
(1 observational 
study) 
⨁◯◯◯ 
VERY LOW a,b 
Data of 1 non-randomized controlled 
study (Akita 2015) 
Quality of life – not reported  - - - - - This outcome was not reported. 
Recurrence (worsening of 
lymphoedema) – not reported  
- - - - - This outcome was not reported. 
Procedure-related adverse events 
follow up: mean 7.8-30.4  
231 per 1.000 0 per 1.000 
(0 to 0) 
not estimable 207 
(4 observational 
studies) 
⨁◯◯◯ 
VERY LOW c,d 
Data of 1 non-randomized controlled 
study (Akita 2015) and 3 prospective 
interventional single-arm studies (Chang 
2013, Cornelissen 2017, Poumellec 2017). 
Procedure-unrelated adverse 
events – not reported  
- - - - - This outcome was not reported. 
Abbreviation: s.s. statistical significant 
a High risk of selection, detection and reporting biases. 
b Small sample size, small number of events. 
c No control group in three studies [10, 20, 21]. 
d Insufficient outcome reporting: Chang [20] reported on 100 patients, but outcome data is only reported for 37 patients. 
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8 Discussion 
Lymphoedema is a chronic and not curable disease and is often accompanied 
with patient morbidity [5]. Lymphoedema is considered to be one of the main 
complications of cancer treatments, especially breast cancer treatments. It has 
a decisive impact on the quality of life of its patients and on their ability to 
work and participation in social activities. Consequently, the improvement 
of patients’ quality of life is the main goal of lymphoedema treatments [21]. 
With the advancement of microsurgical techniques, LVA is gaining popular-
ity and is used as a surgical treatment for extremity lymphoedema regardless 
of the fact its clinical profile is not supported by high-quality data. The pur-
pose of LVA is to relieve lymphatic obstruction and restore normal lymphatic 
function [8, 19, 22]. As reported in the included literature, LVA seems to be 
successful in controlling the progression of early stages of lymphoedema [19]. 
Although it is still a not fully established concept – for example, there is no 
evidence to suggest an optimal diagnosis and ideal duration or frequency of 
treatment, and no evidence to assess the severity or quality of lymphoedema 
which actually correlates with clinical findings. A further difficulty is the un-
derstanding of the optimal patient selection for LVA procedures as well as the 
optimal number of LVAs performed on the patient [4, 20]. Yet with imaging 
modalities such as ICG lymphography the identification of suitable lymphatic 
vessels for LVA procedures improved dramatically, and hence, the right pa-
tient population can be discerned by ICG lymphography [7, 43]. According 
to the literature, there seem to be two factors that determine the effectiveness 
of LVA: the identification of viable lymphatic vessels and the extent of tissue 
fibrosis related to lymphoedema [24]. 
 
Interpretation of the findings 
The aim of this report was to assess the clinical effectiveness and safety of LVA 
compared to the comparator (e.g., VLNT) for the treatment of lymphoede-
ma. A total of 629 articles were identified in the systematic literature search. 
Among them 14 systematic reviews and HTAs on LVA were found, but ex-
cluded for analysis: four of these were systematic literature reviews [2, 5, 31, 
44], one was written in French [11], five were excluded because of different 
aims (e.g., prevention, diagnosis) [4, 9, 16, 45, 46], one systematic review was 
excluded because of inclusion of animal studies [43], and three were found 
potentially relevant, but included also retrospective studies [7, 47, 48]. Despite 
the fact that retrospective studies were included, the evidence converges with 
our findings. 
Our systematic search was not limited to a specific time period, but to spe-
cific study designs – only RCTs, NRCTs, and prospective (controlled) studies 
were included in order to assess outcomes on clinical effectiveness and safety. 
Despite the fact that LVA has been clinically used for decades, we identified 
only one NRCT for assessing the clinical effectiveness and safety of LVA and 
four additional single-arm studies for assessing safety. A total of 217 patients 
were enrolled in the included studies (204 treated with LVA and 13 with 
VSLNT). 
LVA als effektives 
chirurgisches Verfahren 
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Extremitäten angesehen 
ABER: es gibt keine 
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Ziel: Beurteilung der 
klinischen Wirksamkeit 
und Sicherheit der LVA 
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Übersichtsarbeiten 
identifiziert, aber 
aufgrund 
methodologischer 
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LVA und 13 mit VSLNT) 
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Across all studies, LVA was performed slightly different (side-to-end, end-to-
end or end-to-side; primary and/or secondary lymphoedema) and the num-
ber of performed anastomoses differed also across the studies. One important 
finding is that four of the included studies performed different post-inter-
ventional procedures, such as compression bandages in two studies [3, 20] or 
lymphatic drainage in two other studies [10, 22]. The fifth study did not re-
port on this baseline characteristic, but stated the importance of discontinu-
ation of compressive stockings after surgery [21]. Hence, it is currently un-
known, due to conflicting evidence, if peri-interventional procedures such as 
compression therapy directly post-surgery may either harm or benefit the ef-
fectiveness of LVA. Further, it might also be a confounder of the post-pro-
cedural lymphoedema evaluation. 
Details on the applicability of the body of evidence can be found in the Ap-
pendix (see Applicability table). 
Effectiveness data from observational studies 
To proof the clinical effectiveness of LVA procedures, the evidence from RCTs 
is necessary. The lack of RCTs restricted our analysis to NRCTs as the best 
available evidence. We could only identify one NRCT to assess the efficacy of 
LVA due to the lack of trials with a comparative treatment arm. This NRCT 
provided only one outcome on the clinical effectiveness of LVA. Eligible pa-
tients of this study had primary or secondary advanced lower extremity lym-
phoedema. No other inclusion criteria were reported. Because of the absence 
of other NRCT (with regard to upper extremities and different [early] stages 
of lymphoedema), the determination of the best time point at which to per-
form the LVA procedure is difficult to state. 
The only reported outcome in the NRCT was the mean change of volume 
compared with preoperative volumes (difference), however, this outcome was 
deemed important but not crucial to derive a recommendation as it is con-
sidered a surrogate parameter. The improvement in the LVA group was 21.2 
and in the VSLNT group 26.5, with statistical significance in the VSLNT 
group. The difference in volume change can be explained by different num-
bers of patients in the groups (LVA, n=43, vs. VSLNT, n=13) and potential-
ly different underlying lymphoedema (primary vs. secondary). 
Due to the limited number of NRCTs (n=1), we extracted also data from pro-
spective interventional single-arm studies (n=4). However, no conclusions 
on the clinical effectiveness on LVA can be made on the basis of these stud-
ies. Nonetheless, the data from the prospective interventional single-arm stud-
ies show a possible effect concerning crucial and important outcomes (QoL, 
recurrence, and limb volume or circumference reduction). 
Mean volume or circumference reduction was reported in three case series. 
The mean volume difference ranged from 33.5% in [3] to 42% in [20] one 
year postoperatively. Another study reported on lymphoedema improvement 
postoperatively, and a mean overall improvement of 24.7% [10]. One pro-
spective interventional single-arm study reported of a non-significant mean 
change of volume postoperatively of 12.9% for upper extremity lymphoede-
ma [21]. This study was the only case series that had controversial reporting 
on post-interventional treatments such as compression therapy. No report-
ing on volume or circumference reduction was done for lower extremity lym-
phoedema across studies. 
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In the observational studies, the QoL was assessed by various tools. The in-
dividual tools and scores for QoL measurements are further explained in the 
evidence tables (see Appendix Table A-2) where applicable. One study report-
ed improvement in QoL one year postoperatively in eight patients out of 20 
(40%) [21]. Another study only reported on unsatisfactory improvement of 
QoL one year postoperatively, but improvement of functionality (however, 
the number of patients included for this outcome was unclear) [10]. QoL was 
insufficiently reported in two prospective interventional single-arm studies 
[3, 20], and one study had unclear reporting on the questionnaire [10]. 
The outcome on recurrence was only reported in one prospective interven-
tional single-arm study, where four patients (19.7%) stated worsening of lym-
phoedema or recurrence [10]. 
Nonetheless, all the data is reported from prospective interventional single-
arm studies and hence, did not involve control groups and are very prone to 
bias. 
Safety data from observational studies 
In terms of safety, four of the five included studies (one NRCT and three pro-
spective interventional single-arm studies) reported on procedure-related ad-
verse events. Only two patients out of the overall 204 patients across studies 
treated with LVA reported procedure-related adverse events [21], whereas 
three patients out of 13 in the VSLNT group reported adverse events [22]. 
One prospective interventional single-arm study did not report on adverse 
events [3]. Hence, procedure-related adverse events for LVA seem to be rare 
and may only be determined in studies with larger patient samples. 
 
Quality of Evidence 
Overall, the quality of evidence was very low due to high risk of bias in the 
NRCT, the observational study design, insufficient outcome reporting of one 
study, and small sample sizes (see Table 7-1). Further, the included patient 
group in the NRCT was not representative of the range of LVA patients be-
cause only patients with advanced primary and secondary lymphoedema of 
the lower extremities were included [22]. 
The overall risk of bias was considered moderate to high because no randomi-
zation or blinding was performed, and because of insufficient reporting on 
critical outcomes (e.g. QoL), unclear reporting of confounding variables, and 
patients’ consecutive recruitment (see Appendix Table A-3 and Table A-4). 
The included studies in this report demonstrate mixed results following the 
LVA procedures and the quality of these studies varies. A major concern of 
most of the identified prospective interventional single-arm studies is the low 
number of included patients. For instance, one study included only 10 pa-
tients [3]. In order to identify rare procedure related adverse events, low pa-
tient numbers are insufficient. Moreover, only one study had a longer follow-
up period of 12 months [20]. Therefore, reliable data of long-term safety and 
efficacy outcomes are missing. 
The NRCT [22] was conducted in two centres and the other four prospective 
interventional single-arm studies in only one centre. One of these studies in-
cluded 100 patients, but outcome data is only reported on 37 patients and 
baseline data on an unknown number of patients [20]. This may distort the 
effect of LVA. 
1 Studie: Verbesserung 
der QoL (n=8) 
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Consecutive patient recruitment and the prospective study design were un-
clear in one study [10], but the study was still included7. Another study was 
included at first, but excluded after data extraction because of retrospective 
analysis of patient data [8]. 
The utilised LVA methods (end-to-side, end-to-end or side-to-end) and post-
interventional therapies differed slightly between the included studies. For 
instance, in several studies, patients were treated with compression bandag-
es following LVA and in other studies not. It is possible that these treatment 
modalities have had an impact on the recorded outcomes (such as circum-
ference reduction or QoL). 
 
Upcoming evidence 
We identified 3 ongoing studies, which might show effects of LVA with a 
higher quality of evidence: one ongoing randomized controlled trial evaluates 
the improving quality of survivorship for breast cancer-related lymphoedema 
by lymphaticovenous anastomosis compared to complex decongestive thera-
py with the primary outcome of relative arm volume of the affected arm com-
pared to the unaffected arm (estimated completion date May 2019) (NCT-
02790021). 
One ongoing randomized controlled trial evaluates lymphatic venous anasto-
mosis for secondary lymphoedema in comparison with complex decongestive 
physiotherapy with the primary outcome of change in the incidence of cellu-
litis (estimated completion date December 2020) (JPRN-UMIN000025137). 
Another ongoing study is a pilot study on robot-assisted microsurgical lym-
phatico-venular anastomosis evaluating the efficacy of robot-assisted LVA in 
comparison to conventional LVA (estimated completion date February 2019) 
(NTR6465). 
Furthermore, we identified 8 ongoing parallel non-randomized (n=4) and 
single-arm non-randomized studies (n=4). Of those, 5 ongoing studies may 
be connected and may represent sub-analytical results. Further information 
on the eight ongoing observational studies is presented in the Appendix (see 
List of ongoing trials). 
None of the ongoing trials includes patient-relevant outcomes to assess effi-
cacy. Thus, while the study quality might be better due to the comparative 
designs, the crucial outcomes to derive a positive recommendation for LVA 
are probably missing. 
 
Limitations 
First of all, no RCT’s were found in our literature search. Therefore, we de-
cided to include prospective interventional single-arm studies for assessing 
the safety of LVA. We only considered prospective case-series with a patient 
cut-off of at least 10 patients treated for lymphoedema. Presumably, there 
were some prospective studies with less than 10 patients that were not in-
cluded. Furthermore, there were numerous retrospective studies that were 
not included. Since we included also prospective interventional single-arm 
studies, the possibility of systematic errors due to confounding and bias is 
high. 
                                                             
7 A request to the author was made on this behalf but to date no response was received. 
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An additional limitation is that patient-relevant outcomes are missing in the 
included studies. Further, some of the studies rely on subjective reported out-
comes. For example, QoL data are based on subjective VAS scores and may 
be confounded. 
Another limitation of this review is that the studies included varied in terms 
of stages of lymphoedema, localisation of lymphoedema (upper or lower ex-
tremity), and outcomes were not reported separately on primary and second-
ary lymphoedema, this may lead to a variation in efficacy and safety of the 
results. 
Further, there are several studies which describe the use of LVA as preven-
tive procedure after cancer therapies. Hence, LVA may be a role in preven-
tion of lymphoedema [49-51]. As it was not the scope of the assessment, we 
did not include those studies in this report, therefore, we cannot conclude if 
LVA is effective and safe as a prevention treatment for secondary lymphoe-
dema. 
 
Conclusion 
LVA seems to be safe for the treatment of primary and secondary lymphoe-
dema. Nevertheless, no controlled evidence for crucial outcomes could be 
identified evaluating LVA and a comparator. Patient-relevant outcomes, such 
as QoL (pain and functionality) were only described in uncontrolled studies 
and inconsistently reported (e.g., different measurement scales). Because the 
included studies showed poor quality of evidence and high risk of bias, it is 
not possible to draw a reliable conclusion on the clinical effectiveness of LVA. 
Further, there were various methods of LVA performed in the studies, data 
on upper extremity lymphoedema was reported more frequently, and the es-
timation of ongoing post-interventional treatments (e.g., compression treat-
ment etc.) is scarce and presented a large variety. Future RCTs and/or pro-
spective NRCTs need to be performed to find the optimal lymphoedema man-
agement algorithm and to help determine the exact patient group that would 
benefit most from the procedure. In addition, these studies need to be con-
ducted to confirm the outcomes, especially on QoL, and to further knowledge 
of this field. 
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9 Recommendation 
In Table 9-1 the scheme for recommendations is displayed and the  
according choice is highlighted. 
Table 9-1: Evidence based recommendations 
 The inclusion in the catalogue of benefits is recommended.  
 The inclusion in the catalogue of benefits is recommended with restrictions. 
X The inclusion in the catalogue of benefits is currently not recommended. 
 The inclusion in the catalogue of benefits is not recommended. 
 
Reasoning: 
On the basis of the available evidence, we cannot conclude if the assessed pro-
cedure LVA is at least equally effective and safer as the comparator VLNT or 
conservative treatment. Due to the methodological shortcomings of the avail-
able evidence (because only one important outcome, but not decisive for the 
recommendation, was reported in the only comparative study), no conclusions 
are made about the effectiveness of the procedure. There is a need for high-
quality studies due to consistent positive findings based on observational ev-
idence with respect to limb volume reduction. Concerning safety outcomes, 
only procedure-related complications were reported based upon data from one 
NRCT and four prospective interventional single-arm studies. These suggest 
a relatively safe profile of LVA. New study results based on a high-quality 
RCT will potentially influence the effect estimate considerably. 
The re-evaluation is recommended after 2021, if the potentially relevant on-
going studies are completed and only if patient-relevant outcomes are includ-
ed to derive a recommendation (see Appendix List of ongoing trials). Other-
wise, still no conclusions can be drawn on patient-relevant outcomes. 
 
 
Empfehlungsschema 
Evidenz unzureichend 
 LVA derzeit nicht 
empfohlen 
Re-Evaluierung nach 
2021 empfohlen, wenn 
derzeit laufende Studien 
patientInnenrelevante 
Outcomes beinhalten 
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Appendix 
Evidence tables of individual studies included for clinical 
effectiveness and safety 
Table A-1: LVA: Results from one non-randomized controlled study 
Author, year Akita, 2015 [22] 
Country Japan 
Sponsor - 
Intervention LVA 
(side-to-end or end-to-end) 
Lower extremity 
Comparator VSLNT 
Study design Two-centre NRCT 
Setting (e.g. outpatient,  
university hospital etc.) 
University Hospital & Cancer Center 
Number of pts LVA: 43 
VSLNT: 13 
Inclusion criteria Patients with advanced primary or secondary lower extremity lymphoedema 
Exclusion criteria Early stage lymphoedema 
Mean age of patients, yrs (range) LVA: 54.1 (±14.8)8, s.s. 
VSLNT: 63.7 (±7.0) 
Sex, female vs. male (% female) LVA: 40 vs. 3 (93.0) 
VSLNT: 13 vs. 0 (100) 
Mean lymphoedema duration, yrs (range) NR 
Underlying disease (assumingly) cancer (lymph node dissection) & phlegmon in 39 pts (LVA) 
and in 13 pts (VSLNT) 
Assessment of severity of lymphoedema ICG lymphography 
Stage of lymphoedema (e.g.; ISL/Campisi) Early-stage lymphoedema in 63 limbs9 
Advanced stage lymphoedema in 64 limbs 
Follow-up (months) LVA: 18.3 (±8.8) 
VSLNT: 15.1 (±1.9) 
Loss to follow-up, n (%) - 
Pre-interventional procedure (n) Supervised compression therapy (for min. 3 mo before surgery) 
Post-interventional procedure (n) Simple self-lymph drainage after discharge; 
Elastic garments occasionally until the final follow-up 
Additional interventions - 
Diameter of lymphatic vessel, mm NR 
Mean operation time, min LVA: 213 (±68), s.s. 
VSLNT: 414 (±65) 
Mean BMI, kg/m2 LVA: 24.8 (±5.8) 
VSLNT: 23.0 (±2.8) 
Mean number of LVAs performed NR 
Mean preoperative volume differential 
compared with unaffected limb, % 
NR 
                                                             
8 Presumably it is the mean age of patients. 
9 Unclear reporting of lymphoedema staging. 
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Author, year Akita, 2015 [22] 
Outcomes 
Efficacy 
Mean volume or circumference 
reduction, % 
NR 
Mean changes of volume compared  
with preoperative volumes,  
difference % (SD) 
Improvement value of Lower Extremity Lymphoedema index (LEL)10 
LVA: 21.2 (± 2.0) vs. 
VSLNT: 26.5 (± 4.4), s.s. 
Quality of life (QoL), % NR 
Recurrence (worsening of 
lymphoedema), n (%) 
NR 
Safety 
Overall complications, n (%) 0 vs. 3 
Procedure-related adverse events, n (%) LVA group: 0 
VSLNT group: congestion to the skin paddle, 3 (23.1*) 
s.s. 
Procedure-unrelated adverse events, n (%) NR 
* own calculations 
Abbreviations: ICG = Indocyanine green; ISL = International Society of Lymphology; NR = not reported; n.s. not significant; 
LEL = lower extremity lymphoedema; pts = patients; s.s. = statistical significant; VLNT = vascularized lymph node transfer; 
VSLNT = vascularized supraclavicular lymph node transfer; 
 
 
                                                             
10 LEL index: Changes in the postoperative volume were compared using the LEL index, which was calculated from 
the circumferences of 5 points on the limb (the superior edge of the patella, 10 cm above and below the patella, 
the lateral malleolus, and the dorsum of the foot) and the body mass index, which yielded an accurate quantita-
tive assessment of the severity of lymphoedema [22]. 
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Table A-2: LVA: Results from prospective interventional single-arm studies 
Author, year Chang, 2013 [20] Cornelissen, 2017 [21] Damstra, 2009 [3] Poumellec, 2017 [10] 
Country USA Netherlands Netherlands France 
Sponsor Kyte Research and Education Fund; 
National Institutes of Health 
through M. D. Anderson’s Cancer 
Center Support Grant CA016672; 
NR NR NR 
Intervention LVA (lymphovenous bypass) 
(end-to-end or end-to-side) 
89 upper extremities & 11 lower 
extremities 
LVA 
(NR) 
Upper extremity 
LVA 
(end-to-side) 
Upper extremity 
LVA 
(end-to-end) 
Upper extremity 
Comparator - - - - 
Study design Single-centre prospective 
interventional single-arm study 
Single-centre prospective 
interventional single-arm study 
Single-centre prospective 
interventional single-arm study 
Single-centre prospective 
interventional single-arm study11 
Setting (e.g. outpatient, 
university hospital etc.) 
University Hospital Cancer Center University Medical Centre Hospital  
(Lymphoedema Department) 
Day Surgery Setting  
(Breast Cancer Surgery Center) 
Number of pts 10012 20 10 31 
Inclusion criteria  Patients with secondary  
extremity lymphoedema 
 Absence of skin infections and 
complex decongestive therapy for 
at least 3 months; 
 Evidenced upper limb 
lymphoedema secondary to breast 
cancer in stage 1 or 2A according 
to the ISL classification; 
 Patent lymphatic ducts seen by 
ICG lymphangiography; 
 No volume reduction after  
3 months of complex decongestive 
treatment including manual lymph 
drainage, compression therapy, 
and physiotherapy, with persistent 
complaints such as heaviness, pain, 
shoulder function impairment, and 
recurrent attacks of erysipelas; 
 Proven scintigraphic signs of 
obstruction by absence of liver 
uptake and highly pathological 
transport index; 
 Persistent volume excess of more 
than 800cc measured by inverse 
water volumetry; 
 No recurrent malignancy; 
 Good patient compliance and 
willingness to wear therapeutic 
elastic stockings; 
 Operability; 
 Female patient; 
 Age >18 years; 
 Lymphoedema evolving for at 
least 12 months and not 
responding to physiotherapy; 
 History of axillary dissection 
surgery for breast cancer 
treatment; 
 Lymphoedema with at least 2-cm 
augmentation of the circumference 
of the dissected limb compared 
with the healthy limb; 
                                                             
11 Unclear study design. A request to the author was made on this behalf but to date no response was received. 
12 Outcome data is only reported on 37 patients; baseline data reported on an unknown number of patients (lacking table with baseline characteristics). 
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Author, year Chang, 2013 [20] Cornelissen, 2017 [21] Damstra, 2009 [3] Poumellec, 2017 [10] 
Exclusion criteria NR NR NR  No previous physiotherapy for 
lymphoedema; 
 Refusal to sign informed consent; 
Mean age of patients, 
yrs (range) 
54.0 55.9 (range, 51.9-59.9) 58.7 (range, 46-68) 64 (range, 38-65) 
Sex, female vs. male  
(% female) 
NR 20 vs. 0 (100) 10 vs. 0 (100) 31 vs. 0 (100) 
Mean lymphoedema 
duration, yrs (range) 
Upper extremity: 3.5 (range, 1-10)
12
 
Lower extremity: 6.6 (range, 1-25) 
6 (range, 2-30) 5.3 (range, 3-14) NR 
Underlying disease Upper extremity lymphoedema: 
breast cancer (n=89); 
Lower leg extremity lymphoedema: 
sarcoma (n=3), melanoma (n=2), 
gynecologic cancer (n=6) 
Breast cancer 
Skin infection in 5 pts. (25%) 
Breast cancer Breast cancer 
Assessment of severity 
of lymphoedema 
ICG lymphangiographic findings NR NR NR 
Stage of lymphoedema 
(e.g.; ISL/Campisi) 
Unclear
9
 ISL 
Stage 1: n=1 
Stage 2A: n=19 
Campisi staging 
Stage III (n=10) 
NR 
Follow-up (months) Upper extremity: 30.4 (range, 3-84) 
Lower extremity: 18.2 (range, 1-36) 
7.8 (range, 6.3-9.3) 12 Mean 12.8
14
 
Loss to follow-up, n (%) NR Unclear13 - unclear 
Pre-interventional 
procedure (n) 
ICG lymphography (n=65); ICG lymphangiography Standardized conservative treatment 
for 3 months; 
Perioperative usage of antibiotics; 
NR 
Post-interventional 
procedure (n) 
Compression bandages and elevation 
of affected limb; 
Prophylactic intravenous antibiotics; 
4 weeks after surgery: use of 
compression garments 
NR Compression bandages and elevation 
of affected limb at night; 
Elastic stockings during follow-up 
Removal of the sleeve and lymphatic 
drainage physiotherapy beginning 
two weeks post surgery 
Additional interventions VLNT due to no improvement after 
LVA (n=1) 
NR NR NR 
Diameter of lymphatic 
vessel, mm 
Upper extremity: 0.2-1.0 
Lower extremity: NR 
NR ≤ 0.3 NR 
                                                             
13 Unclear reporting of losses to follow-up. 
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Author, year Chang, 2013 [20] Cornelissen, 2017 [21] Damstra, 2009 [3] Poumellec, 2017 [10] 
Mean operation time, 
min 
Upper extremity: 240  
(range, 3-5 hrs) 
Lower extremity: NR 
92 (range, 84-100) 60 120
14
 
Mean BMI, kg/m2 Upper extremity: 30 (range, 20-51) 
Lower extremity: 31 (range, 22-42) 
25.1 (range, 21-33) NR 25.3 (± 6.4)14 
Mean number of LVAs 
performed 
Unclear15 1.5 unclear16 NR 
Mean preoperative 
volume differential 
compared with 
unaffected limb, % 
Upper extremity: 32 (range, 1-112) 
Lower extremity: 37.6 (range, 7-85) 
NR 35.2 (range, 20-50) NR 
Outcomes     
Efficacy     
Mean volume  
or circumference 
reduction, % 
Overall17: 
3 mo postoperatively: 33 
6 mo postoperatively: 36 
12 mo postoperatively: 42 
Lymphoedema stage I or II  
(upper extremity, 30 pts): 
3 mo postoperatively: 58 
6 mo postoperatively: 52 
12 mo postoperatively: 61 
Lymphoedema stage III or IV  
(upper extremity, 30 pts): 
3 mo postoperatively: 12 
6 mo postoperatively: 16 
12 mo postoperatively: 17 
NR Mean volume difference: 
12 mo postoperatively: 33.5 (range, 
18-49) 
Herpertz circumferential 
measurement: improvement of 4.8% 
1 year postoperatively 
Overall lymphoedema decrease 
postoperatively18: 
Stage II: 29.5% 
Stage III: 13.1% 
Stage IV: 0% 
Mean overall decrease: 24.7% 
Mean changes of  
volume compared with 
preoperative volumes, 
difference % (SD) 
Upper extremity19:  
3 mo postoperatively: -9.6 (9.1), s.s. 
6 mo postoperatively: -8.5 (11.2), s.s. 
12 mo postoperatively: -7.7 (8.2), s.s. 
Lower extremity: NR 
Upper Extremity Lymphoedema 
index (UEL-index): 
Preoperatively: 14.92 (±8.01) 
Postoperatively: 12.99 (±7.47), n.s.  
Herpertz method at 0–12 months 
1.7* 
NR 
                                                             
14 Different numbers in text compared to baseline data table. 
15 It is reported to be 5.6 (in pts with ICG lymphography), but patient group is unclear. 
16 It is reported that at least 3-4 anastomoses are performed, but only 11 LVA procedures in 10 patients. 
17 Unclear number of total patients. Insufficient data on lower extremity lymphoedema. 
18 Data extracted from the discussion section. 
19 Unclear number of total patients. 
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Author, year Chang, 2013 [20] Cornelissen, 2017 [21] Damstra, 2009 [3] Poumellec, 2017 [10] 
Quality of life (QoL), % Insufficient reporting Mean VAS Scores according  
to the Lymph-ICF questionnaire 
(Dutch version)20 
Overall 
Preoperatively: 44 (n=20) 
3 mo postoperatively: 31 (n=8), s.s. 
6 mo postoperatively: 30 (n=8), s.s. 
12 mo postoperatively: 14 (n=8), s.s. 
Physical Function Domain 
Preoperatively: 48 (n=20) 
3 mo postoperatively: 26 (n=8), s.s. 
6 mo postoperatively: 46 (n=8) 
12 mo postoperatively: 13 (n=8), s.s. 
Mental Function Domain 
Preoperatively: 42 (n=20) 
3 mo postoperatively: 22 (n=8), s.s. 
6 mo postoperatively: 15 (n=8), s.s. 
12 mo postoperatively: 11 (n=8), s.s. 
Household Activities Domain 
Preoperatively: 52 (n=20) 
3 mo postoperatively: 42 (n=8) 
6 mo postoperatively: 33 (n=8), s.s. 
12 mo postoperatively: 28 (n=8), s.s. 
Mobility Activities Domain 
Preoperatively: 41 (n=20) 
3 mo postoperatively: 36 (n=8) 
6 mo postoperatively: 33 (n=8) 
12 mo postoperatively: 11 (n=8), s.s. 
Life and Social Activities Domain 
Preoperatively: 41 (n=20) 
3 mo postoperatively: 39 (n=8) 
6 mo postoperatively: 28 (n=8), s.s. 
12 mo postoperatively: 11 (n=8), s.s. 
SF 36 questionnaire21 QoL evaluation questionnaire22: 
1 yr postoperatively: <4 
(unsatisfactory) 
Functionality: 
55% score of >7  
(significant funtional improvement) 
29% scores 4-7  
(moderate functional improvement) 
Recurrence (worsening 
of lymphoedema), n (%) 
- NR NR 4 (19.7) 
                                                             
20 Lymphoedema international classification of functioning (Lymph-ICF) questionnaire (Dutch version): This questionnaire comprises five domains. The values range from 1 to 100; 
a lower score on the questionnaire indicates a better quality of life. The Lymph-ICF questionnaire gives a score on five different domains, which may provide a wider coverage of 
all the aspects related to lymphoedema. This questionnaire can determine changes over time and may provide useful and detailed information for long-term follow-up. Further-
more, the used questionnaire is the only lymphoedema-related questionnaire that uses a VAS score answering model, which is more sensitive to subtle changes [21]. 
21 Unclear reporting on the questionnaire: 0-6 months postoperatively: slight subjective improvement in 5 patients who felt less disabled. 
22 Unclear reporting on the questionnaire. 
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Author, year Chang, 2013 [20] Cornelissen, 2017 [21] Damstra, 2009 [3] Poumellec, 2017 [10] 
Safety - 2 (10)   
Overall complications, 
n (%) 
- Skin irritation at the site of contrast 
injection, 2 (10) 
NR - 
Procedure-related 
adverse events, n (%) 
NR NR NR - 
Procedure-unrelated 
adverse events, n (%) 
  NR NR 
* own calculations 
Abbreviations: ICG = Indocyanine green; ISL = International Society of Lymphology; NR = not reported; n.s. = not significant; LEL = lower extremity lymphoedema; pts = patients;  
s.s. = statistical significant; VLNT = vascularized lymph node transfer; 
 
 
Risk of bias tables and GRADE evidence profile 
Internal validity of the included studies was judged by two independent researchers. In case of disagreement a third researcher was involved to solve the differ-
ences. A more detailed description of the criteria used to assess the internal validity of the individual study designs can be found in the Internal Manual of the 
LBI-HTA [52] and in the Guidelines of EUnetHTA [53]. 
Table A-3: RoBANS risk of bias assessment tool for non-randomized controlled studies, see [26] 
Study  
reference/ID 
Selection  
of participants 
Confounding 
variables 
Intervention (exposure) 
measurement 
Blinding of  
outcome assessment 
Incomplete  
outcome data 
Selective  
outcome reporting 
Overall  
Risk of Bias 
Akita, 2015 [22] High23 Unclear24 Low High25 High26 High27 Moderate to High28 
 
                                                             
23 No randomization. 
24 Unclear reporting of confounding variables. 
25 No blinding of outcome assessors. 
26 Only reporting on one important, but not crucial outcome. 
27 Critical outcomes (e.g., QoL, pain) not reported. 
28 Not intended to produce an overall rating. 
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Table A-4: Risk of bias – study level (case series), IHE checklist, see [27] 
Study  
reference/ID 
Chang, 2013 
[20] 
Cornelissen, 
2017 [21] 
Damstra,  
2009 [3] 
Poumellec,  
2017 [10] 
Study objective 
1. Was the hypothesis/aim/objective of the study clearly stated? Yes Yes Yes Yes 
Study design 
2. Was the study conducted prospectively? Yes Yes Yes Unclear
29
 
3. Were the cases collected in more than one centre? No No No No 
4. Were patients recruited consecutively? Yes Yes Unclear
29
 Unclear
29
 
Study population 
5. Were the characteristics of the patients included in the study described? Partial
30
 Yes Yes Partial19 
6. Were the eligibility criteria (i.e. inclusion and exclusion criteria) for entry into the study clearly stated? Partial
31
 Partial
31
 Partial
31
 Yes 
7. Did patients enter the study at a similar point in the disease? Unclear
32
 Yes Yes Unclear
32
 
Intervention and co-intervention 
8. Was the intervention of interest clearly described? Yes Partial Yes Yes 
9. Were additional interventions (co-interventions) clearly described? Yes Yes Yes Yes 
Outcome measures 
10. Were relevant outcome measures established a priori? No Yes Yes Partial
33
 
11. Were outcome assessors blinded to the intervention that patients received? Unclear
34
 Unclear
34
 Unclear
34
 Unclear
34
 
12. Were the relevant outcomes measured using appropriate objective/subjective methods? Partial
35
 Yes Yes Partial
35
 
13. Were the relevant outcome measures made before and after the intervention? Unclear
36
 Yes Yes No 
                                                             
29 Not explicitly stated in the study. 
30 See extraction tables in the Appendix for reporting on baseline characteristics. 
31 No exclusion criteria were stated. 
32 No reporting on staging of lymphoedema. 
33 Not all outcome measures were stated a priori. 
34 No information on blinding was available. 
35 Insufficient reporting on QoL. 
36 Volume measurements were made pre- and postoperatively, but the other outcomes were only reported postoperatively. 
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3 
Study  
reference/ID 
Chang, 2013 
[20] 
Cornelissen, 
2017 [21] 
Damstra,  
2009 [3] 
Poumellec,  
2017 [10] 
Statistical Analysis 
14. Were the statistical tests used to assess the relevant outcomes appropriate? Yes Yes Unclear Unclear 
Results and Conclusions 
15. Was follow-up long enough for important events and outcomes to occur? Yes Yes Yes Yes 
16. Were losses to follow-up reported? No Unclear
37
 Yes Unclear
37
 
17. Did the study provided estimates of random variability in the data analysis of relevant outcomes? Partial Partial Partial No 
18. Were the adverse events reported? Yes Yes No Yes 
19. Were the conclusions of the study supported by results? No No No No 
Competing interests and sources of support 
20. Were both competing interests and sources of support for the study reported? Unclear
38
 Unclear
38
 No Unclear
38
 
Overall Risk of Bias High Moderate Moderate High 
 
  
                                                             
37 Discrepancy between text and tables/figures in patient numbers for loss to follow-up. 
38 Either reporting on conflict of interest or funding, not both. 
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Table A-5: Evidence profile: efficacy and safety of LVA surgical treatment in lymphoedema 
Certainty assessment № of patients Effect 
Certainty Importance № of 
studies 
Study  
design 
Risk of 
bias Inconsistency Indirectness Imprecision 
Other 
considerations LVA VSLNT 
Relative 
(95% CI) 
Absolute 
(95% CI) 
Mean changes of volume compared with preoperative volume measurements (follow up: mean 15.1-18.3 months) 
1 observational studies  
(before-after study) 
very 
seriousa 
NA (only 1 
trial) 
not serious very 
seriousb 
none Improvement value of LEL index: 
LVA: 21.2 (±2.0) vs. VSLNT: 26.5 (±4.4), s.s. 
⨁◯◯◯ 
VERY LOW 
IMPORTANT 
Quality of life – not reported 
- - - - - - - - - - - - CRITICAL 
Recurrence (worsening of lymphoedema) – not reported 
- - - - - - - - - - - - IMPORTANT 
Procedure-related adverse events (follow up: mean 7.8-30.4) 
4 observational studies  
(before-after studies) 
very 
seriousc 
not serious not serious not serious publication bias 
strongly suspectedd 
2/194 
(1.0 %) 
3/13 
(23.1 %) 
not 
estimable 
not 
estimable 
⨁◯◯◯ 
VERY LOW 
CRITICAL 
Procedure-unrelated adverse events – not reported 
- - - - - - - - - - - - IMPORTANT 
Abbreviation: s.s. = statistical significant 
comments: 
a High risk of selection, detection and reporting biases. 
b Small sample size, small number of events. 
c No control group. 
d Chang reported on 100 patients, but outcome data is only reported for 37. 
Nomenclature for GRADE table:  
Limitations: 0: no limitations or no serious limitations; -1: serious limitations  
Inconsistency: NA: Not applicable (only one trial); 0: no important inconsistency; -1: important inconsistency  
Indirectness: 0: direct, no uncertainty, -1: some uncertainty, -2 major uncertainty  
Other modifying factors: publication bias likely (-1), imprecise data (-1), strong or very strong association (+1 or +2), dose-response gradient (+1), Plausible confounding (+1)  
 
 
Appendix 
LBI-HTA | 2018 65 
Applicability table 
Table A-6: Summary table characterizing the applicability of a body of studies 
Domain Description of applicability of evidence 
Population All studies included mostly female patients with lymphoedema (primary or secondary to cancer 
treatment). Two studies only included patients with advanced lymphoedema, which is likely to have 
influenced the effects of the procedure. The studies included a total of 204 patients with LVA 
treatment and 13 patients with VSLNT treatment. The mean age of included patients was consistent 
across studies and ranged from 54.0-64.0 years. The inclusion criteria and the population in the 
studies seem to be in accordance with the intended patient population for the procedure. 
Intervention Patients in the included studies were treated with LVA in primary or secondary lymphoedema of  
the upper and/or lower extremities. The procedure was performed either side-to-end, end-to-end or 
end-to-side. The diameter of lymphatic vessel was described in two studies for upper extremities and 
ranged from 0.2 to 1.0 mm. Three studies did not report on the  diameter of lymphatic vessels on 
which the LVAs were performed. 
In most of the studies, pre-interventional (e.g. standardized conservative methods, compression 
therapy) as well as post-interventional (e.g. compression bandages, lymphatic drainage) treatments 
were performed. It is unclear if variations in the performed methods of LVA or the additional 
performed treatments (pre- and post-interventional) are likely to have a meaningful impact on 
patient outcomes. 
Comparators One study was comparing LVA and VSLNT. The VSLNT procedure may represent an alternative to the 
LVA procedure, but may be more effective in advanced stages of lymphoedema, as this study showed. 
To date, we found no published RCTs in which LVA is compared to conservative or other surgical 
treatments, such as VLNT/VSLNT. 
Outcomes None of the crucial outcomes for clinical effectiveness were reported in the only included NRCT. 
Only one important outcome, mean changes of volume, was reported in this study. The time period 
for this outcome was not reported in the study. The outcome of clinical effectiveness showed a 
potential benefit of the treatment with VSLNT in comparison to LVA for patients suffering from 
advanced lymphoedema. 
The most frequently reported critical outcome for safety was procedure-related adverse events 
across studies. One prospective interventional single-arm study did not report this outcome. For the 
safety assessment only, two patients (2/204) reported adverse events of LVA during the procedure 
(skin irritation after contrast injection). 
However, the presented data in the included studies is limited, especially due to small sample sizes in 
some of the studies, unclear reporting of patient numbers in one study (which may lead to imprecise 
data), and no reporting of critical outcomes for efficacy data in the controlled study. 
Setting The procedure was performed under local or general anaesthesia. One study was a non-randomized 
controlled two-centre study carried out in Japan. The other four studies were  single-centre prospective 
interventional single-arm studies conducted in the US (1) and Europe (3). The studies carried out in 
Europe were based in the Netherlands (2) and France (1). 
The studies were published between 2009 and 2017. The procedure was performed in university 
hospitals and/or cancer centres across four studies. In one study, LVA was performed in a day 
surgery setting because of its minimal invasiveness and short recovery time. 
The settings of the studies reflect the clinical settings in which the technology is intended to be used 
in an appropriate way. No applicability issues are expected from the geographical setting. 
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List of ongoing trials 
Table A-7: List of ongoing randomised controlled trials of LVA 
Source Identifier/Trial name Patient population Intervention Comparison Primary Outcome 
Primary 
completion date Sponsor 
ClinicalTrials.gov NCT02790021 
Improving Quality  
of Survivorship for 
Breast Cancer-related 
Lymphoedema by 
Lymphaticovenous 
Anastomosis:  
A Randomized 
Controlled Trial 
Woman >18 years old; treated for early stage 
breast cancer and underwent an SLNB, ALND 
or axillary radiotherapy; early stage 
lymphoedema of the arm (stage 1 or 2a on  
ISL classification); excess limb volume ≥10% 
(relative volume of the unaffected arm 
compared to the affected arm); previously had 
three months conservative therapy (standard 
of care); primary breast cancer; Unilateral 
disease/treatment; 
Lymphatic-
ovenous 
anastomosis 
(LVA) 
Complex 
decongestive 
therapy 
Relative arm volume of 
the affected compared 
to the unaffected arm 
May 2019 Maastricht 
University 
Medical 
Center 
WHO-ICTRP JPRN-UMIN000025137 
Lymphatic Venous 
Anastomosis for 
Secondary 
lymphoedema 
Male and Female; patients who received 
lymphatic surgery/reconstructive surgery; 
patients diagnosed with secondary lower 
extremity lymphoedema by lymphoscintigraphy; 
patients judged to have the ability to answer 
interrogation; patients who obtained document 
consent by the patients themselves freely with 
sufficient understanding after receiving 
sufficient explanation for participation in this 
study; in cases where the patient is a minor;  
in addition to the patient caregiver sufficient 
understanding, document consent is obtained; 
Lymphatic 
venous 
anastomosis 
Complex 
decongestive 
physiotherapy 
Change in the number 
of times of cellulitis. 
(Cellulitis is defined as 
having inflammatory 
findings such as redness 
and heat sensation on 
the affected limbs and 
having a fever of 38.5 
degrees or more.) 
December 2020 Saiseikai 
Kawaguchi 
General 
Hospital 
WHO-ICTRP NTR6465 
Pilot study on robot-
assisted microsurgical 
lymphatico-venular 
anastomosis Pilot study 
on robot-assisted micro-
surgical lymphatico-
venular anastomosis 
Female gender; age 18 years or older;  
treated for primary early stage breast cancer; 
early stage lymphoedema of the arm  
(stage 1 or 2 on ISL classification); ELV ¡Ý10%; 
suffering unilateral disease and treatment; 
Robot-
assisted LVA 
Conventional 
LVA 
Efficiency of LVA is 
measured assessing the 
quality of the completed 
lymphovenular 
anastomosis 
February 2019 Maastricht 
University 
Medical 
Center 
(MUMC+); 
Microsure 
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Table A-8: List of ongoing trials of LVA (parallel non-randomized and single-arm non-randomized studies) 
Source 
Identifier/ 
Trial name Study type Patient population Intervention Comparison Primary Outcome 
Primary 
completion 
date Sponsor 
ClinicalTrials.
gov 
NCT02020837 
A Pilot Study 
Assessing the Effect 
of Lymphaticovenous 
Micro-Anastomosis 
in the Treatment of 
Postmastectomy 
Lymphoedema 
Single-arm 
non-
randomized 
18-70 years of age;  
stage II-IV unilateral 
lymphoedema 
Lymphaticovenous 
Micro-Anastomosis 
- Changes relative to baseline in 
the volume of the affected limb 
at 3 and 6 months from surgery 
September 
2019 
University 
of 
Arkansas 
WHO-ICTRP JPRN-
UMIN000017768 
Study of the 
effectiveness of 
early lymphatic 
venous anastomosis 
Single-arm 
non-
randomized 
Male and Female; ≤ 90 years-old; 
secondary lymphoedema 
patients 
LVA - Circumference of the leg  
(LEL index); the presence or 
absence of cellulitis 
NR The 
University 
of Tokyo 
Hospital 
WHO-ICTRP JPRN-
UMIN000022689 
Examination of the 
lymphoedema 
improvement with 
the surgical combi-
nation therapy for 
secondary limbs 
lymphoedema 
Parallel non-
randomized 
≤30 years old, male and female, 
patients with secondary 
lymphoedema, and expect 
surgical cure; persons who are 
available for LVA conducts LVA 
by ICG lymphangiography; 
persons with LVA treatment 
resistance receive LNT or 
VLNT+LVA; years-old 
Vasculized lymph 
node 
transfer(VLNT) 
Vasculized lymph 
node transfer, 
Lymphaticovenuler 
anastomosis  
(LVA) 
vs. 
Lymphaticovenuler 
anastomosis 
Limbs circumference,  
ICG fluorescent lymphography, 
SF36 
NR Cancer 
Institute 
Hospital 
WHO-ICTRP JPRN-
UMIN00001914039 
Prospective study on 
the effectiveness 
assessment of 
Indocyanine Green 
Lymphography and 
Lymphatic Surgery 
for lymphoedema 
and lymphatic 
disease. 
Parallel non-
randomized 
Male and female; all subjects 
included in this study are lym-
phoedema and lymphatic disease 
patients undergoing surgical 
treatment at our department 
who have been fully informed 
of all clinical tests, question-
naires, surgical treatments, and 
the purpose and analysis of this 
study and have all consented in 
writing. No age restriction and 
exclusion criteria were set. 
Indocyanine green 
(ICG) 
lymphography and 
Lymphatic venous 
anastomosis 
(Modified Campisi's 
LVA for subclinical 
and early-stage 
lymphoedema) 
ICG 
lymphography 
and lymph node 
transfer 
& 
ICG 
lymphography 
and liposuction 
Pre and postoperative course, 
limb circumference, tissue stiff-
ness; echogram, CT, MRI, lym-
phoscintigraphy, indocyanine 
green lymphography, and lym-
phoangiography obervations; 
blood; histopathological analysis; 
clinical; health-related QOL 
analysis using Short Form (SF)-36 
Health Survey; patient weight; 
general physical and image 
observations 
March 
2018 
Saiseikai 
Kawaguchi 
General 
Hospital 
                                                             
39 These studies may be connected and may represent sub-analytical results. 
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Source 
Identifier/ 
Trial name Study type Patient population Intervention Comparison Primary Outcome 
Primary 
completion 
date Sponsor 
WHO-ICTRP JPRN-
UMIN000027759
39
 
Prospective study on 
the effectiveness 
assessment of 
Indocyanine Green 
Lymphography and 
Lymphatic Surgery 
for lymphoedema 
and lymphatic 
disease. 
Single-arm 
non-
randomized 
Male and female; all subjects 
included in this study are 
lymphoedema and lymphatic 
disease patients undergoing 
surgical treatment at our 
department who have been 
fully informed of all clinical 
tests, questionnaires, surgical 
treatments, and the purpose 
and analysis of this study and 
have all consented in writing. 
No age restriction and 
exclusion criteria were set. 
Indocyanine green 
(ICG) 
lymphography and 
ultrasound for the 
patency rate of 
Lymphatic venous 
anastomosis(LVA) 
- Pre and postoperative course, 
limb circumference, tissue stiff-
ness; echogram, CT, MRI, lym-
phoscintigraphy, indocyanine 
green lymphography, and lym-
phoangiography obervations; 
blood; histopathological analysis; 
clinical; health-related QOL 
analysis using Short Form (SF)-36 
Health Survey; patient weight; 
general physical and image 
observations; patency rate of 
lymphatic venous anastomosis. 
NR Saiseikai 
Kawaguchi 
General 
Hospital 
WHO-ICTRP JPRN-
UMIN000014748
39
 
Prospective study on 
the effectiveness 
assessment of  
Indocyanine Green 
Lymphography and 
Lymphatic Surgery 
for lymphoedema 
and lymphatic 
disease. 
Parallel non-
randomized 
Male and female; all subjects 
included in this study are 
lymphoedema and lymphatic 
disease patients undergoing 
surgical treatment at our 
department who have been 
fully informed of all clinical 
tests, questionnaires, surgical 
treatments, and the purpose 
and analysis of this study and 
have all consented in writing. 
No age restriction and 
exclusion criteria were set. 
Indocyanine green 
(ICG) 
lymphography and 
Lymphatic venous 
anastomosis (LVA) 
ICG 
lymphography 
and lymph node 
transfer 
& 
ICG 
lymphography 
and liposuction 
Pre and postoperative course, 
limb circumference, tissue stiff-
ness; echogram, CT, MRI, lym-
phoscintigraphy, indocyanine 
green lymphography, and lym-
phoangiography obervations; 
blood; histopathological analysis; 
clinical; health-related QOL 
analysis using Short Form (SF)-36 
Health Survey; patient weight; 
general physical and image 
observations. 
NR Saiseikai 
Kawaguchi 
General 
Hospital 
WHO-ICTRP JPRN-
UMIN000021762
39
 
Prospective study on 
the effectiveness 
assessment of 
Indocyanine Green 
Lymphography and 
Lymphatic Surgery 
for lymphoedema 
and lymphatic 
disease. 
Parallel non-
randomized 
Male and female; >20 years 
old; All subjects included in 
this study are lymphoedema 
and lymphatic disease patients 
undergoing treatment at our 
department team (including 
collaboration with other 
hospital team) who have been 
fully informed consented. No 
age restriction and exclusion 
criteria were set. 
Indocyanine green 
(ICG) 
lymphography and 
Lymphatic venous 
anastomosis (LVA) 
ICG 
lymphography 
and drug 
treatment 
& 
ICG 
lymphography 
and radiological 
treatment 
Pre and postoperative course, 
limb circumference, tissue stiff-
ness; echogram, CT, MRI, lym-
phoscintigraphy, indocyanine 
green lymphography, and lym-
phoangiography obervations; 
blood; histopathological analysis; 
clinical; health-related QOL 
analysis using Short Form (SF)-36 
Health Survey; patient weight; 
general physical and image 
observations; analysis of 
chylous and volume of chylous 
thoracs and ascites. 
December 
2020 
Saiseikai 
Kawaguchi 
General 
Hospital 
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Source 
Identifier/ 
Trial name Study type Patient population Intervention Comparison Primary Outcome 
Primary 
completion 
date Sponsor 
WHO-ICTRP JPRN-
UMIN000025891
39
 
Prospective study on 
the effectiveness 
assessment of 
Indocyanine Green 
Lymphography and 
Lymphatic Surgery 
for lymphoedema 
and lymphatic 
disease. 
Single-arm 
non-
randomized 
Male and female; Saitamaken 
Saiseikai Kawaguchi General 
Hospital patients who 
received lymphatic surgery/ 
reconstructive surgery; 
patients diagnosed with 
secondary lower extremity 
lymphoedema by lympho-
scintigraphy; patients judged 
to have the ability to answer 
interrogation; patients who 
obtained document consent 
by the patients themselves 
freely with sufficient 
understanding after receiving 
sufficient explanation for 
participation in this study; in 
cases where the patient is a 
minor, in addition to the 
patient caregiver sufficient 
understanding, document 
consent is obtained. 
Indocyanine green 
(ICG) 
lymphography and 
Lymphatic venous 
anastomosis (LVA) 
- Pre and postoperative course, 
limb circumference, tissue stiff-
ness; echogram, CT, MRI, lym-
phoscintigraphy, indocyanine 
green lymphography, and lym-
phoangiography obervations; 
blood; histopathological analysis; 
clinical; health-related QOL 
analysis using Short Form (SF)-36 
Health Survey; patient weight; 
general physical and image 
observations. 
NR Saiseikai 
Kawaguchi 
General 
Hospital 
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Literature search strategies 
Search strategy for Cochrane 
Search Name: Lymphatovenous anastomosis for lymphoedema 
Search Date: 14/12/2017 
ID Search 
#1 MeSH descriptor: [Lymphoedema] explode all trees 
#2 lymphoedema* (Word variations have been searched) 
#3 lymphoedema* (Word variations have been searched) 
#4 lymph-edema* (Word variations have been searched) 
#5 lymph-oedema* (Word variations have been searched) 
#6 lymph* near (edema* or oedema*) (Word variations have been searched) 
#7 #1 or #2 or #3 or #4 or #5 or #6 
#8 MeSH descriptor: [Anastomosis, Surgical] explode all trees 
#9 (lymphoven* or lymphaticoven* or lymphatic vein*) near (anastomos* or bypass* or shunt* or surg* or 
micro*surg*) (Word variations have been searched) 
#10 LVA:ti,ab,kw (Word variations have been searched) 
#11 #8 or #9 or #10 
#12 #7 and #11 
Total: 12 Hits 
 
 
Search strategy for CRD (DARE, NHS-EED, HTA) 
#### Lymphovenous anastomosis for lymphoedema 
Search Date: 14/12/2017 
1 MeSH DESCRIPTOR Lymphoedema EXPLODE ALL TREES 
2 (Lymphoedema*) 
3 (Lymphoedema*) 
4 (lymph* NEAR (edema* OR oedema*)) 
5 #1 OR #2 OR #3 OR #4 
6 MeSH DESCRIPTOR Anastomosis, Surgical EXPLODE ALL TREES 
7 ((lymphoven* OR lymphaticoven* OR lymphatic vein*) NEAR (anastomos* OR bypass* OR shunt* OR surg* 
OR micro*surg*)) 
8 (LVA) 
9 #6 OR #7 OR #8 
10 #5 AND #9 
Total: 4 Hits 
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Search strategy for Embase 
No. Query results Results Date 
#9 #4 AND #8 531 14 Dec 2017 
#8 #5 OR #6 OR #7 1,804 14 Dec 2017 
#7 lva:ti,ab 1,184 14 Dec 2017 
#6 ((lymphoven* OR lymphaticoven* OR 'lymphatic vein*') NEAR/5 (anastomos* OR 
bypass* OR shunt* OR surger* OR surgic* OR micro*surg*)):ti,ab 
446 14 Dec 2017 
#5 'lymphovenous anastomosis'/exp 468 14 Dec 2017 
#4 #1 OR #2 OR #3 21,937 14 Dec 2017 
#3 (lymph* NEAR/5 (edema* OR oedema*)):ti,ab 2,798 14 Dec 2017 
#2 lymph*edema*:ti,ab 11,777 14 Dec 2017 
#1 'lymphoedema'/exp 18,558 14 Dec 2017 
 
 
Search strategy for Medline via Ovid 
Database: Ovid MEDLINE(R) <1946 to December Week 1 2017>, Ovid MEDLINE(R) Epub Ahead of Print 
<December 13, 2017>, Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations <December 13, 2017>, Ovid 
MEDLINE(R) Daily Update <December 13, 2017> 
Search Date: 14.12.2017 
Search Strategy: 
1 exp Lymphoedema/ (11581) 
2 lymph?edema*.mp. (11925) 
3 (lymph* adj5 (edema* or oedema*)).mp. (2108) 
4 1 or 2 or 3 (15993) 
5 exp Anastomosis, Surgical/ (89367) 
6 ((lymphoven* or lymphaticoven* or lymphatic vein*) adj5 (anastomos* or bypass* or shunt* or surger* or 
surgic* or micro?surg*)).mp. (410) 
7 LVA.ti,ab. (924) 
8 5 or 6 or 7 (90457) 
9 4 and 8 (432) 
10 remove duplicates from 9 (407) 
 
 
  
 
 
